A mutation in a mouse J-protein that functions in the diphthamide biosynthesis pathway by Webb, Thomas Robert
A Mutation in a Mouse J-protein that
Functions in the Diphthamide
Biosynthesis Pathway
Thomas Robert Webb




I've been in Edinburgh for just over four years and there are a lot of
people who've helped me to get where I am now - writing the last page of my
thesis, whahey!!
First I need to thank Ian, who has now been my supervisor for nearly 3
and a half years. Its been a great project and I've really enjoyed my time in
the lab, and the nights drinking, we'll have to do the Hallion again sometime.
I'd like to thank everyone else in the lab, past and present for all the help
they've given me. So far all things science over the past 3 or so years I need
to thank Sally for her supervision, and Alan, Pleasie, Katrine, Peter,
Margaret, and all the people who've left; Ian, Darren, Sapna, and almost
Tom. Special thanks to Lisa for all the mouse stuff and DNA making. There
must be other people who I've forgotten, but I've only had an hours sleep in
the last couple of days, and that was on the office floor. I know I'll be back up
again soon and I'll see you all then (I need to sort everything out, and tidy
things up - I'm not sure if I've got enough time to tidy my
desk/bench/freezer/other stuff).
Thanks to all the other students and other heavy drinkers for all the
drinking nights, especially Dan, for buying me an engagement ring (for Anna,
I did pay him back, but there were funny looks in the jewellers). If anyone's
down in London please get in touch with me and Anna and we'll show you
the sights and smells.
I'd like to thank my parents for so much help over the past few years,
both for their personal and financial support, and for their help with our flat.
After 8 years of student hardship I'm finally starting a proper job (in 5 days
time, for anyone else reading this, some good advice would be to arrange a
holiday and not a job for your first week after finishing).
I have to save my biggest thanks for Anna, who I met as soon as I
arrived in Edinburgh, and is the best thing that could have happened to me in
my time here. I don't think I would have had any chance of finishing this
thesis on time without her, or being organised to have a job arranged
i
(constant nagging "constructive panic" is very effective). We've both been
through the same thing in writing our theses, and we've coped remarkably
well, however, housework should be done by both of us (especially an
aversion to washing up).
I've had a great time in Edinburgh, I'll miss the place and everyone
I've met here, (although most have headed for London), so thanks to
everyone for making the last 4 years so enjoyable. Next time I'm up I'm sure
I'll see you all in t'pub.
I'm sorry if I've forgotten to specifically thank anyone else, but I've
been in work for over thirty hours, and I'm getting a bit tired, which probably
explains much of the waffle.
11
Declaration
The experiments described in this thesis were the unaided work of the author except
where acknowledgement is made by reference. No part of this work has previously
been accepted for any other degree, nor is any part of it being submitted concurrently





Chromosomal deletions can be used in mutagenesis strategies that screen for
recessive phenotypes. Several mouse chromosomal deletions are available which
remove the Pax6 gene and result in the small-eye phenotype. Deletion of the
syntenic region in humans results in the phenotypically variable WAGR syndrome.
The Pax6Sey~1H deletion spans 3 Mb and includes 15 genes. This deletion has been
used in an ENU mutagenesis screen for phenotypes revealed when hemizygous with
the deletion. One such mutation, which is lethal against the Pax6Sey~1H deletion, has
been found from 233 pedigrees. Mice heterozygous for the mutation are
phenotypically normal. When homozygous the mutation is generally lethal by El4,
and embryos have retarded growth from as early as E9. However, some homozygous
mice are born which are small and have extra digits on one or both hind limbs.
Sequencing of the genes in the deletion interval identified a splice site mutation in
Dnajc20 a member of the J-domain family of molecular chaperones. The mutation
causes the in frame skipping of exon 4, leading to an mRNA that encodes a protein
with an internal 23 amino acid deletion.
The yeast orthologue of Dnajc20 has recently been identified as one of five
genes required for the biosynthesis of diphthamide, a post-translational modification
that is unique to translation elongation factor 2 (eEF2), the target of diphtheria toxin
and Pseudomonas exotoxin A. Here it is shown that the mutation in the mouse
Dnajc20 protein results in the abolition of diphthamide on eEF2 in these animals.
Additionally mice mutated for Dnajc20 show remarkable similarity to the phenotype
of Ovcal mutant mice. Ovcal is a tumour suppressor whose yeast orthologue was
also identified as being required for diphthamide biosynthesis. The phenotypes of
these two mutations suggest that the diphthamide biosynthesis pathway, which is
conserved from archaebacteria to eukaryotes but absent in eubacteria, is essential for
normal mammalian development and survival. Furthermore the human orthologue of
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The past ten years has seen the sequencing of the genomes of humans ' and an
increasing number of model organisms3"6. This has been a landmark achievement in
biology, providing a mass of information concerning genome structure and content. The
challenge now is functional genomics, the determination of a biological role of all the
genes in the human genome. Evidence of gene function can be obtained by studying the
expression of genes and their distribution in normal tissues. However, the most
powerful tool in the dissection of gene function is through generation of mutations and
their subsequent characterisation. The use of mutation in the identification of gene
function will be achieved through the use of model organisms. The major model
organisms including, yeast (Saccharomyces cerevisiae), fruitfly (Drosophila
melanogaster) (referred to here as Drosophila), worm (Caenorhabditis elegans), and the
mouse (Mus musculus), are proven tools for the study of gene function and the
publication of the genomes for each of these organisms has increased their effectiveness
in functional genomics. Each of these models already has a substantial mutant resource




1.2 Eukaryotic mutation and conservation
The mouse has emerged as the best model for the study of human gene function and
study of the pathogenesis of human disease. This is largely due to the fact that of the
advanced model organisms, it is the mouse that is most similar to humans. However, the
mouse has a relatively small mutant resource, comparing the number of mutations to the
number of genes. The study of mutations in the mouse has been performed for as long
as it has been a model organism. It was mouse fanciers, breeding coat colour variants at
the turn of the last century, who were essentially responsible for the start of mouse
genetics and many spontaneous mutations in the mouse have now been maintained for
many years. The use of radiation to mutagenise the mouse in the mid-20th century
rapidly increased the mutant resource. However, it is only relatively recently, with the
large increase in markers and the genome project, that large-scale mutagenesis of the
mouse has become viable, and the aim of creating at least one mutation per gene a
possibility. The use of mutagenesis in the mouse will be introduced more fully in
Chapter 2.
It is almost 10 years since the yeast genome was published, bringing with it the
possibility for vast, genome wide, gene function studies3. The aim of creating one
mutation per gene has been achieved in yeast, where close to a comprehensive collection
of yeast deletion strains has been produced7. The yeast has already been a very
successful model in the dissection of fundamental biological processes, for example
3
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many of the genes regulating cell cycle were identified as cell division mutations in the
8 10different yeast species " . Now, large-scale phenotype screens make use of the global
deletion resource, identifying changes in growth rate due to the presence of stressors or
chemicals, in the dissection of particular processes, or even in a search for human
disease genes11"13. A genome-wide mutation resource has other uses besides global
screens. Small mutagenesis screens are still performed with the deletion strains
providing a quick resource for confirming the mutated loci. The deletion strains are also
used for the study of mammalian genes. Human or mouse genes can be used to replace
a yeast orthologue in investigations of functional equivalence, a powerful tool in the
identification of gene function.
In Drosophila, phenotype-driven mutagenesis has been enormously successful in the
identification of genes required for embryonic development14. Large-scale mutagenesis
screens have been performed using either the chemical mutagen EMS (ethylmethane-
sulphonate) or P-element transposons. The screens have been particularly efficient at
identifying genes in a particular pathway, for example, the components of the Wnt
signalling pathway were first identified by mutagenesis of Drosophila5. Modifier
screens, where mutations are sought that alter an already sensitised background, have
also been efficient in Drosophila, specifically with the identification of genes relevant to
human neurodegenerative disorders16. A problem with the phenotype-driven screens in
Drosophila has been the mapping of EMS-induced mutations. Only recently, with the
4
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identification of markers, and the ability to map mutations to the genome sequence has
the usefulness of phenotype driven screens in Drosophila been improved.
The large number of mutations generated by genotype-driven screens, such as the yeast
deletion resource7, and the RNAi approach in worm, which covers the majority of the
worm genes17, as well as the easier identification of mutations induced in phenotype
driven screens means that there is now a vast eukaryotic mutant resource.
The genome sequencing effort of recent years has allowed a vast increase in the
identification of conserved gene families both within a single species and across
multiple species. This ability to compare evolutionary conserved gene families among
18the different model organisms is one of the major benefits of the post-genomic era .
The Gene Ontology consortium has assigned standard annotations to gene products,
which describe the biological process, the molecular function and the cellular
component or location, based upon the characterised roles of genes within conserved
families19.
The public availability of information allows a large amount of information about gene
function to be quickly identified. The presence of large amounts of conservation
between the genes of different eukaryotes means that the investigation of a particular




A combination of mutation and conservation provides the basis for the work detailed
within this thesis, from the isolation of a developmentally relevant gene by mutagenesis
of the mouse, to the identification of its biological role by inference from its recently
identified yeast orthologue.
1.3.1 Mutagenesis in the mouse
Our group has recently perfonned a small ENU mutagenesis screen targeted to a region
ofmouse chromosome 2 around the Pax6 and Wtl genes. Chapter 2 introduces the use
of mutagenesis in the mouse and gives the background to this screen. The screen
isolated a mutation that results, predominantly, in embryonic lethality. The embryos are
small, developmentally delayed and have Polydactyly of the hind limbs. The mutation,
by the nature of the screen, was localised to a particular chromosomal region.
Sequencing of the genes within the region identified a mutation in a functionally novel
J-protein. The orthologous human protein, along with the rest of the chromosomal
region is syntenic with human chromosome 1 lp 13. Deletion of this region in humans
results in WAGR syndrome (Wilm's tumour, Aniridia, Genitourinary abnormalities and
mental Retardation). Recently WAGR patients have been identified with very similar
Polydactyly to that observed in the mutant mice20'21. Chapter 5 describes the human
6
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syndrome in more detail, as well as an investigation as to whether the orthologous
human J-protein is the cause of the Polydactyly in these patients.
1.3.2 J-proteins; homologues and orthologues
The mutated J-protein has previously been named mmDjc7 in mouse22, however, the
mammalian J-protein family has been complicated in recent years by a number of
changes of nomenclature. Chapter 3 describes the identification ofmouse J-proteins and
the clarification of the mouse J-protein family. We therefore suggest the name Dnajc20
for this particular gene, in line with the current nomenclature. The bacterial DnaJ
protein provides the name for the J-protein family, a large family of molecular
chaperone proteins that are conserved throughout prokaryotes and eukaryotes. Chapter
3 provides a detailed introduction to the J-proteins, as well as their chaperone partners,
the Hsp70s.
The Dnajc20 protein is conserved throughout eukaryotic evolution (See Chapter 3), and
it was the identification of these sequence orthologues that consequently resulted in the




Recently, through the investigation of mutations in yeast that result in resistance to
diphtheria toxin, Liu et a I identified the yeast orthologue of Dnajc20 as one of the
proteins required for the synthesis of diphthamide23. Diphthamide is a post-translational
modification that is only found on translation elongation factor 2 (eEF2)24. ADP-
ribosylation of diphthamide by diphtheria toxin or Pseudomonas exotoxin A results in
the inhibition of protein synthesis and cell death. The diphthamide residue was
o c
originally identified 25 years ago , however its function in normal cellular physiology is
still unknown. Chapter 4 introduces this process and describes the investigation of
diphthamide in the mutant Dnajc20 mice. Another of the factors required for
9 ^
diphthamide biosynthesis in yeast is the orthologue of mouse Ovcal . This gene has
recently been knocked out in the mouse26 and has a very similar homozygous phenotype
to the Dnajc20 mutant mice. Together these two mice show a requirement for
diphthamide in normal mammalian development and postnatal survival. Furthermore,
the Ovcal heterozygous mice spontaneously develop tumours, potentially linking
diphthamide and Dnajc20 to tumourigenesis.
8
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2.1 Introduction
l 2 6The availability of the complete sequence of both the human ' and mouse genomes has
revealed the volume of the coding potential of the mammalian genome. The task ahead
is to decipher the diverse function of the estimated 25-30,000 genes. In an effort to meet
this challenge there has been an escalation in the application of mutagenesis screens in
the mouse. These studies aim to provide an insight into the function of a gene via the
result of its mutant phenotype.
2.1.1 Mouse mutagenesis
There are essentially two mutagenesis schemes that can be employed in the production
of mouse mutants; genotype-driven and phenotype-driven. Genotype-driven
mutagenesis of the mouse involves the construction of transgenic lines, whereby the
gene of interest is knocked out or is disrupted by a knock in. This strategy requires an
interest in a particular gene and is generally performed on those genes that have been
very well studied, meaning that novel loci are ignored. Gene-trap mutagenesis provides
a genotype-driven strategy for the systematic genome wide screening for mouse
mutations. This mutagenic approach involves the insertion of marker transgenes into the
genome of ES cells. If this marker integrates within an active gene, that gene becomes
disrupted and is tagged by the marker, allowing straightforward identification of the
mutated loci. Theoretically, the random disruption of genes in a gene-trap mutagenesis
10
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screen could work as a phenotype driven approach. However, the easy identification of
the mutated gene and the cost of going from an ES cell to a mouse mean that a mutation
remains in ES cell form until it becomes interesting to an investigator, and therefore, is
used in a genotype-driven manner.
Phenotype-driven mutagenesis of the mouse involves the use of the chemical mutagen
A-ethyl-A-nitrosourea (ENU), which randomly generates single base pair changes
throughout the genome. This approach makes no prior assumption concerning the
nature of the genes involved with the interest being confined to a particular phenotype.
A large number of mice are screened for the phenotype of interest, and following the
identification of such animals, the mutated loci can be mapped by breeding the animals
and utilising the genetic markers available. It is the time and cost of this mapping that is
the major disadvantage of phenotype-driven compared to the genotype-driven screens.
The major difference between a gene-trap based genome wide screen and an ENU
mutagenesis strategy is the type of mutation generated. A gene-trap disrupts a gene
resulting, in the production of a null allele, in the majority of cases. ENU mutagenesis
causes a greater variety of mutations ranging from null alleles to hypermorphs. This
range of alleles provides the chief benefit of ENU mutagenesis, as it gives a better
reflection of the mutations causing human disease, and are therefore the best way to
dissect the pathogenesis of human conditions. Furthermore, point mutations allow a
series of mutations to be generated within the same gene, which may give different
11
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phenotype and allow the identification of functionally relevant features within a gene
product.
2.1.2 Mode of action of ENU
ENU is an alkylating agent that predominantly induces point mutations via the transfer
of its ethyl group to oxygen and nitrogen radicals at a number of sites within the
nucleotides; the 02, 04, or N3 of thymine, Nl, N3, or N7 of adenine, 02 or N3 of
cysteine, and 06, N3, or N7 of guanine27'28. The presence of the ethyl group on a
nucleotide is called a DNA adduct, and this structure can result in mispairing during the
next round of DNA replication, leading to a base pair substitution. The most common
ENU generated mutations in the mouse are AT to TA transversions, and AT to GC
transitions29, and are the result ofmispairing adducts at 02 and 04 of thymine28.
The mutagenic action of ENU is most potent in male spermatogonia! stem cells29. ENU
is administered by intraperitoneal injection, which due to its cytotoxicity, renders the
mice sterile. Fertility recovers by repopulation from stem cells that harbour mutations.
Specific locus experiments indicate the mutation rate in mouse using ENU is in the
region of lO"3 per locus per gamete, meaning that for every 1000 gametes from a
mutagenised male there may be a mutation in any gene of interest30. However, the rate
of mutation in any particular gene can vary significantly, depending on various factors,
12
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including; the size of the gene, the number of splice sites and the coding length, the
presence of domains or regions important for the overall structure and function of the
protein, and potentially the presence of hot spots in certain regions of the genome. The
mutation rate at the genome level has been shown to be around one base change per
megabase ofDNA31.
2.1.3 ENU Mutagenesis Strategies
The efficiency of ENU, as well as its low cytotoxicity, makes it the most useful mutagen
for phenotype-driven screens in the mouse. A number of approaches have been used in
the generation ofmutant animals, but the method used essentially depends on whether it
is a screen for dominant or recessive mutations. Dominant screens have a simple genetic
design, whereby male mice are injected with ENU and then mated with untreated
females. The progeny from this cross are the G1 test class, and these are screened for
the phenotype of interest. Affected animals are bred to confirm the heritability of the
abnormality, and intercrossing allows the homozygous phenotype to be studied. Figures
for dominant screens suggest a heritable mutant phenotype is present in at least 2% of
the G1 animals32'33.
Recessive screens require a more complex strategy for the recovery of the test class.
The first step is the same as in the dominant screens; mutagenised males are mated with
untreated female mice to produce the G1 progeny. Each G1 mouse represents an
13
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individual mutant line that may be heterozygous for many recessive mutations. These
G1 animals are mated with wild-type mice to produce a G2 progeny, with a 50% chance
of inheriting any recessive mutations from the G1 founder. Backcrossing these G2
animals to the G1 generation will result in G3 progeny that can undergo phenotypic
analysis. Of the G3 progeny 25% will be homozygous for the particular mutation.
Figures for recessive screening strategies suggest that up to 30% of the G3 animals will
carry a heritable mutation34.
2.1.4 Region based screens
The production of mutations using genome-wide recessive screens is slow and time
consuming. However, recessive mutations can be recovered more quickly in the
particular regions of the genome that are covered by deletions and inversions. In these
screens the G1 progeny from ENU treated males are mated to mice that carry a deletion
that covers a defined chromosomal region. This will result in a phenotype due to
hemizygosity in the mice that inherit the ENU induced mutation from one parent and the
deletion from the other parent. A benefit of this strategy is the immediate localisation of
a mutation to the chromosomal region covered by the deletion, avoiding the need to map
the mutation.
Regionally directed mutagenesis screens have been performed against well-defined
genetic intervals and generally employ visible marker loci. For example, a mutagenesis
14
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project directed against the albino, Tyr, locus on mouse chromosome 7 has been
undertaken . This screen isolated 13 mutations from 972 gametes with phenotypes
ranging from embryonic lethality and runting, to neurological defects. The strategy that
Rinchik et al employed in their screen involved the mutagenesis of male mice
homozygous for the recessive albino mutation in tyrosinase. These mice were mated
with wild-type females to produce an F1 progeny that were heterozygous for the albino
marker and had a heterozygous mutagenised genome, with the possibility of a mutation
in the vicinity of the albino locus. The G1 progeny were then mated with a deletion-
carrying class that were hemizygous for the chinchilla mutation in tyrosinase. The use
of these coat colour mutations allowed the quick scoring of the G2 progeny; with the test
class (those with a possible ENU induced mutation against the deletion) were albino,
and the carriers of any induced mutation were light chinchilla (due to the compound
albino/chinchilla genotype). The other G2 progeny were wild-type.
ENU mutagenesis screens such as that performed by Rinchik et al have many benefits;
they allow the generation of recessive mutations over two generations, the scoring of
potential mutations by phenotyping, and any mutation will be mapped to a relatively
small region30.
15
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2.2 Background
2.2.1 A region based screen in the mouse Pax6 region
Our group, in collaboration with MRC Harwell, has recently completed a small ENU
screen for recessive mutations directed against the region of mouse chromosome 2
around the Pax6 gene. The region is of interest for several reasons; firstly there are a
number of mouse mutations, the Small eye (Sey) alleles, which have been well
characterised. These mutations include point mutations within the Pax6 gene, as well as
deletions that remove up to several megabases of DNA. These deletions, which have
made the screen possible, are associated with a number of growth defects when
heterozygous, and cause early lethality when homozygous. Secondly, the syntenic
chromosome region in humans, 1 lp 13, is deleted in the phenotypically variable WAGR
syndrome, consisting of Wilms' tumour, aniridia, genitourinary abnormalities, and
mental retardation (this human syndrome will be discussed in more detail in chapter 5).
Finally, the phenotypes of the deletions in the mouse and humans are not fully explained
by the individually mutated genes, suggesting the presence of further loci within this
region that are important for growth and survival, as well as the cause of the early
embryonic lethality.
16
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2.2.2 The Pax6 region
The Pax6 region on mouse chromosome 2, along with the syntenic region on human
chromosome 11 p 13, is a locus defined by mutation; the Small eye alleles in mouse and
WAGR syndrome in humans. The Small eye phenotype resembles human aniridia, and
displays a similar pattern of inheritance, thus providing a mouse model for a human
disease35'36. The mapping of WAGR chromosomal markers to the region of mouse
chromosome 2 near the Small eye locus, revealed that not only did the Sey alleles
provide a model for aniridia; the deletion alleles could also represent a model for
WAGR syndrome . The subsequent identification that human WT1 and PAX6 genes
were responsible for Wilms' tumour and aniridia respectively led to the identification of
the genes in the mouse38'39.
The first of the Small eye alleles arose spontaneously and is due to a point mutation in
Pax6, resulting in premature termination before the homeobox domain and loss of
function of Paxd38'40. The Pax6Sey mutation causes small eyes, cataracts, and no iris in
heterozygous animals. Homozygotes are born with no eyes or nose and die soon after
birth35'36'40. Several other point mutations have been generated in Pax6 by ENU
mutagenesis. The Neuherberg series of Pax6 alleles include 8 nonsense mutations,
which would result in truncated proteins, all of which have phenotypes suggesting null
alleles41'42. Of the other Pax6Nu' alleles, Pax64Ne" has a missense mutation in its
homeodomain, and Pax67KiU is a result of a change in the Kozak consensus sequence.
17
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The first deletion alleles to be identified were Pax6Sey'Dey and Pax6Sey~1H, both of which
remove the Wtl and Pax6 genes43' . The heterozygous and homozygous phenotypes of
mice carrying these deletion alleles are more severe than the Pax6Sey point mutation.
The Pax6Sey'Dey allele arose spontaneously and the Pax6Sey',H allele was induced by the
X-ray irradiation of oocytes. Animals heterozygous for these two alleles are 10-20%
smaller than their wild-type littermates and have reduced viability. The most obvious
characteristic of these animals is a white spot on their belly. There is prenatal loss of
around two thirds of deletion heterozygotes, and homozygotes die around
preimplantation43'45. Compound Pax6SeyIPax6Sey~1H heterozygotes display a more severe
phenotype than the Pax6Se> homozygotes, being smaller throughout embryonic
development and more retarded in facial development.
The Sey deletion alleles do not replicate the Wilms' tumour or genitourinary
abnormalities caused by the heterozygous loss of the WT1 gene in humans, even though
in both the Pax6Sey~Dey and Pax6Sey~IH deletion carriers Wtl is deleted. These findings
suggest that mouse development is not as susceptible to Wtl loss as human
development37. Targeted mutagenesis has been used to create null Wtl mice46. The Wtl
heterozygotes are normal, but the homozygotes die at around embryonic day 15,
revealing that in mouse the loss of one copy of Wtl is not sufficient to replicate the
human abnormalities.
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The increased severity of the Sey deletions compared to loss of Wtl or Pax6 in mouse,
and as the additional features ofWAGR syndrome (particularly mental retardation), has
led to a lasting interest in the region. However, only a small number of other genes have
been identified between Wtl and Kcna4, the genes representing the end points of the
Pax6Sey~IH deletion47. Reticulocalbin, a Ca2+ binding protein of the endoplasmic
reticulum, has been localised to the region between Wtl and Pax6. Another gene, Elp4
AO
(originally Paxneb), was identified immediately distal of Pax6 . Interestingly, intron 9
of this gene was shown to contain control elements of Pax6, which also result in aniridia
when mutated. The only other known genes that have been localised to this region were
Fshb and Kcna4, which are towards the distal breakpoint of the Pax6Sey~w deletion.
However, these genes are not removed by the Pax6Sey~Dey deletion. The similar
phenotypes produced by Pax6Sey'Dey and Pax6Sey'm deletions suggest that loss of either
Fshb or Kcna4 does not result in any overt phenotype47. Therefore, there must either be
novel mutations in those genes already identified or other novel loci responsible for
features of the Sey deletion alleles and WAGR syndrome.
2.2.3 The strategy of the screen
The Sey deletions on mouse chromosome 2 are appropriate tools for performing a region
based ENU mutagenesis screen. The recessive screen provides a platform for the
identification of developmentally relevant genes, as well as the further dissection of the
deletion phenotypes that currently cannot be explained totally by the known genes in the
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region. The synteny between this region of mouse chromosome 2 and the human
WAGR region implies that any mutations identified will have relevance to the human
syndrome.
Similar to other region specific screens, visible marker loci are utilised in the form of the
Small eye mutations to track the mutagenised genome over two generations. However,
unlike other region based screens there are no viable recessive alleles available to use as
a marker (such as the albino mutation used by Rinchik et al30). Instead this breeding
strategy involves the use of a heterozygous marker mutation, the Pax6Sey'Neu allele. This
mutation is semi-dominantly inherited, with heterozygous mice displaying
micropthalmia. The mutation is embryonic lethal when homozygous, therefore, no
novel alleles of Pax6 will be recovered in this screen due to the likely embryonic
lethality of any compound heterozygous progeny of the first cross.
The screen was originally designed against three of the Small eye deletion alleles,
Pax6Sey'lH, Pax6Sey2H, and Pax6Sey'3H. The use of multiple deletions allows the further
mapping of mutations via complementation testing. However, the low fitness and
fecundity of the larger of these deletions, Pax6Sey2H and Pax6Sey 3H, meant that they were
uneconomical for use in screening. Therefore, only the Pax6Scy~'H allele was used.
The scheme for the region-based screen for recessive mutations is shown in figure 2.1.
ENU treated BALB/c males are mated with females heterozygous for the Pax6Sey~Neu
20
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mutation; producing G1 progeny with a heterozygous mutagenised genome against the
Pax6 marker allele. G1 Pax6Sey'~Nev heterozygotes are selected, as these identify the
animals that potentially carry an ENU-induced mutation in the region of interest
inherited from the mutagenised BALB/c male. The Pax6Sey Neu heterozygotes are crossed
with a deletion carrier to produce four theoretical G2 progeny classes; a potential carrier
of an ENU induced mutation, the potential mutation against the deletion (the test class),
a Pax6Sey~Neu carrier, and the theoretical Pax6Sey~Neu/Pax6Sey~1H compound mice. This
Pax6Sey~NeuIPax6Sey~IH compound genotype is lethal and therefore, will not be seen in the
F2 progeny.
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Figure 2.1 ENU mutagenesis screen against the Pax6 region
Male BALB/c mice were treated with ENU, possibly inducing a mutation in the
desired region (yellow box), and mated with heterozygous Paxd^iP*" (red
box) females. The progeny of this cross that carried the Pax6s*y-fl*>u mutation
were investigated for the presence of a heritable mutation on the other
chromosome by crossing to the Pax6Sey-1H mice. The progeny of the this cross
contains the test class, which is identifiable by the Pax6s*y-1H mutation. If no
Pax6s*y~1H mice are born, a recessive lethal mutation has been induced.
22
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The Pax6Scy,H carriers are the test class, and can be distinguished from the Pax6SeyNeu
mice by phenotype (Pax6Sey'IH carriers are smaller and have the white belly spot). The
Pax6Sey'n1 mice can be examined for a modified phenotype, implying the presence of a
recessive mutation in the region. If the Pax6Sey'w class is absent, a recessive lethal
mutation may have been induced. Recessive lethal mutations can be retrieved from the
carriers. The transmission rate of the Pax6Sey ,H deletion chromosome is 34%, giving
expected test class progeny numbers at a ratio of approximately 2x carrier to lx deletion
carrier to 2x Pax6Sc} Ne" carrier. This gives a probability of finding no deletion carriers
by chance at less than 1% when there are more than 20 offspring.
2.2.4 The MUTS1/14 mutation
One mutation has been retrieved from 233 fully tested lines. This mutation, MUTS1/14,
was found to be lethal against the Pax6Sey ,H deletion. Out of 35 F2 progeny there was
one animal detected carrying the Pax6Sey'1H deletion chromosome, compared to the
expected number of seven. The surviving Pax6Sey~IH deletion mouse might be the result
of a "leaky" lethal phenotype due to a penetrance effect. Or, more likely, a
recombination event within the deletion region, whereby a cross-over between the
Pax6Sey'Neu allele and the induced mutant locus results in the mutation being inherited by
the Pax6Sey'Ne" carriers instead of the Pax6Sey~lH test class.
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Carrier mice from the MUTS1/14 line were intercrossed to characterise the homozygous
phenotype. MUTS1/14 homozygotes were occasionally viable, however in the majority
of homozygotes the mutation resulted in embryonic lethality (Table 2.1). One fifth of
the expected number of MUTS1/14 were born, and of these only three reached weaning,
two were dead at birth, and four were euthanised due to poor health by postnatal day 2.
The homozygotes that were born were small (Figure 2.2.A), with some having one or
more extra digits on either one or both hind limbs (Figure 2.2.B and C). Figure 2.2.D
illustrates the preaxial Polydactyly of the MUTS1/14 mice. It shows a bone stain of the
right hind limb of one of the MUTS1/14 animals that was dead at birth (this experiment
was performed subsequent to the work at MRC Harwell, see Materials and Methods).
There is total duplication of digit 1 and partial duplication of digit 2. Animals with one
extra digit showed duplication of digit one only. This phenotype differs from the more
common form of preaxial Polydactyly, which involves the "mirror image" duplication of
any of digits 2-5.




Homozygote 9 Small, extra digits on one or both
hindlimbs
Table 2.1. Intercrossing the MUTS1/14 carriers. A fifth of the expected number of
homozygotes were born. Of these only 3 reached weaning, 2 were dead at birth, and 4 were
euthanised.
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Figure 2.2 MUTS1/14 homozygous mice.
A small number of MUTS1/14 homozygous mice were born in intercrosses
performed at MRC Harwell. The MUTS1/14 homozygous mice are smaller than their
wild-type littermates. 2.2.A Homozygous MUTS1/14 embryo (left) with a
wild-type littermate. 2.2B and 2.2.C, preaxial Polydactyly on hind limbs of MUTS1/14
homozygous mice. 2.2.D Alizarin red/alcian blue bone staining of the right hind limb
of a MUTS1/14 pup born at MRC Harwell and euthanised at P, showing preaxial
Polydactyly. There is complete duplication of digit 1, and bifurcation of a second digit.
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The MUTS1/14 mutation is known to be in a gene within the Pax6SeyIH deletion
interval, which is approximately 3Mb in size, and includes the genes between Wtl and
Kcna441. However, recombination events during the breeding of MUTS1/14 carriers
reduced the size of the candidate interval. Recombination events in two mice resulted in
the homozygosity of the mutagenised BALB/c chromosome telomeric of the D2MU100
marker. As both mice were phenotypically wild-type, the mutation was localised
between the proximal breakpoint of the Pax6Sey lH deletion and the D2MU100 marker.
Therefore the MUTS1/14 mutation was confined to a 1.4 Mb region between the Wtl
gene and the D2MU100 marker.
2.2.5 Identification of candidates for the MUTS1/14 mutation
At the outset of this investigation the annotation of this region of mouse chromosome 2
was poor, with only 4 known genes being present in the 1.4Mb region around Pax6; the
Pax6 gene itself, Wtl, Ren and Elp4 (originally published as Paxneb). At the same time
as the ENU screen was undertaken, the UK Mouse Sequencing Project began the high
quality sequencing of this region, as well as other sections of chromosomes 4, 13, and X.
Using this sequence information 1 was able to characterise the coding potential of the
region between Wtl and D2MU100 via comparative sequence analysis and gene
prediction49. This analysis identified the presence of at least 8 genes and 61 exons.
Subsequently, a 9 exon gene, DCDC1, was identified in humans50 and is also present in
mice. My original analysis had combined the C-terminus of this gene with the N-
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terminus of the 4732421G10Rik gene. Dcdcl and 4732421G1ORik produce related gene
products. Both proteins contain one doublecortin domain (DCX), and as the other
proteins in this family contain two of these domains, my original investigation resulted
in the misannotation of these two genes. The updated list of genes is included in Table
2.2 and Figure 2.3.
Table 2.2 Candidate genes
Gene (Mouse) Exons Comments
Wtl 10 Tumour suppressor gene




Ca' -binding protein of the endoplasmic
reticulum
Pax6 11 Paired domain and a homeodomain
containing developmental regulator
Elp4 10 Homologue of the yeast elongator complex
subunit ELP4
1500034J2ORik 8 Homologue of yeast IMP 1
Dnajc20 5 Homologue of the bacterial heat-shock
(.1700030A21Rik) protein DnaJ
Dcdcl homologue 9 Expressed in testis and brain, contains
doublecortin domain
4732421G1ORik 5 Contains doublecortin domain
Table 2.2. The 9 genes encoded between the proximal breakpoint of the Pax6Sey'1H deletion and
the D2MH100 marker.
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Figure 2.3 Candidate genes for MUTS1/14
The position of the 9 candidate genesforthe MUTS1/14 mutation on
mouse chromosome 2.
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2.3 Results
2.3.1 Identification of a splice mutation in a J-protein
To identify the base change responsible for the MUTS1/14 phenotype I sequenced the
exons of several of the genes in the candidate region. As the MUTS1/14 homozygous
phenotype is universal growth retardation, the gene responsible would be expected have
a wide expression pattern. The first genes sequenced were chosen due to their EST
coverage and were Elp4, 1500034J20Rik, Dnajc20. Although the Wtl null phenotype
does not resemble the MUTS1/14 homozygotes, it was also sequenced due to the
expression of a Wtl YAC transgene between the developing digits of the hindlimbs51
(however, as expected no mutation was identified in Wtl).
The sequencing of the exons of the candidate genes revealed the presence of one base
change, a T to A transversion at position +2 of the splice donor site in intron 4 of
Dnajc20 (Figure 2.4.A). The +2 position of a splice donor site is 100 % conserved and
is required for correct splicing of a transcript 52. Mutations at this position in numerous
other genes have previously been reported and always result in the skipping of the
adjacent exon . To test the effect of the identified base change on the splicing of the
Dtiajc20 mutant transcript RT-PCR analysis was performed. Figure 2.4.B shows the
amplification of the Dnajc20 transcript from wild-type, heterozygote, and homozygote
RNA between exons 3 and 5.
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A
B
Figure 2.4 A splice mutation in Dnajc20
A. Sequence view of the exon/intron boundary, with position +2
highlighted, illustrating the T to Atransversion. Top sequence is from
a wild-type, wild-type, middle sequence is from a heterozygote,
bottom sequence is from a mutant.
B. RT-PCR between exon3and exon5 of Dnajc20. Lane 1 is wild-type,
2 isfrom a hetero zygote, 3 is from a mutant. The higher band
represents the presence of exon4,the lower band represents the
skipping of exon 4. The hetero zygote sample contains both bands at
approximately equal levels.
C. Schematic of Dnajc20 splicing in the wild-type and in the
hetero zygote.
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The expected wild-type amplified product from RT-PCR of the Dnajc20 transcript
between exon 3 and 5 is 246bp. This corresponds to the size of the band from the wild-
type sample, and the larger band in the heterozygote (Figure 2.4.B). The amplified
product of the mutant sample, and the smaller band in the heterozygote sample, is
approximately 69bp smaller (Figure 2.4.B), equivalent to the skipping of exon 4.
Sequencing of the RT-PCR product of the mutant sample confirmed the absence of
Dnajc20 exon 4 in the MUTS1/14 mutant line. Figure 2.4.C illustrates the splicing of
the Dnajc20 transcript in the MUTS1/14 mutation.
Dnajc20 is a 5 exon gene, with the start site being present in exon 2 and a TGA
termination codon in exon 5 (Figure 2.5). The mutation in the MUTS1/14 animals
results in the in-frame skipping of exon 4 (highlighted in Figure 2.4), which would
essentially result in a 23 amino acid deletion in the encoded protein. The production of
an mRNA transcript at approximately wild-type levels by the mutant allele (best
observed in the heterozygous RT-PCR product in Figure 2.4.B) suggests that a protein
may be made. The potential protein product of the Dnajc20 mutation is investigated in
chapter 4. This 23 amino acid deletion would not disrupt the J-domain of Dnajc20,
which is encoded by exons 2 and 3, but it would remove the beginning of a C-terminal
zinc finger present in this protein (Figure 2.5). The identification of this C-terminal
domain will be reported in Chapter 3 and its functional relevance discussed in chapter 4.
As the MUTS1/14 mutation has been identified, further references will refer to the
Dnajc20 mutation.
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GCTTTCCGTC CGGCTCCCGC AGCAAG7GGA C7CC7GCTCC AAAG7GAAGC GCCA7A AG7i_ 60
TGACGCTGTG TGGAGCCAGG GGAAGGCA7C AGCAGGGACA GCC7CGG7GG GGCGGACGCC 120
TGCCTGTGGA CGCCGCCTGT CCGCC AAGCT GCCGCTGCTT CAGGG7CA7C AGAGAAGGCT 180
CCCTTCTAGG TCAAAGGACG CTGATGGCT7 TGGAGCAGAC ACTCAAAAAG GA7TGGTACA 240
M A L E Q T L K K D V Y
GCATTCTGGG TGCAGACCCA 7C7GCAAA7A 7G7CAGACC7 AAAACAA AAA 7A7CAGAAAC 300
S I L G A D P SAW M S D L K 0 K Y O K
TCATA7TACT GTATCATCCA GA7AAACAAA G7GCAGA7G7 GCCAGCTGGA ACCA7GGAGG 360
L I L L Y H P D K O S A D V PAG 7 « E
AGTGTATGCA GAAGTTTAT7 GAAATTGATC AGGCA7GCAA AA7TC7AGGG AA7GAAGAAA 420
ECHO K F I E I D Q A V K I L G H E E
GTA7GACC7G CAGCGGCATG
TKKK Y D I QRH
. T A . 7 GCGCCT7GAA GAGA7G7CCT GGAACC AAG TGATGAA7C7 TTC77TCTGA
D A O V RLE EMS V N QB: D E S F S L
GCTG7CGATG TGG7GGGAAA TACAC 7G7CT CCAAGGATGA AGCACAAGAA GCCACCCTCA
S C R C G C K Y T V S K D E A 0 E A 7 L
TCTCCTGTGA CGCGTGCTCG CTGATTGTGG AGCTCCTCCA TCAGAGCTGA GCTGCGTC7T 660
I S C D A CS LIV EILQ Q S •
CTGCCCTCGG 7CC77TAC~AA CAAGGACACA GA7GC7TTC7 TGTTATTCAA GATGGTCTTC 720
AAGCAAAACC ACTTAAGATT AACAA ATTAA TTCAGTTTTT TATATGT ATC TAAAATGTAA 780
ATTATAGGAT ATTACAAGAA GGACTTGAAT AATATTTTTG CACTTTTAGC TAACAACTTT 840
TGTTTTCTCTT TGGTACAAA CTAATGATTT CCTTTTTGAA GTATAAATAT CTTTTTCAAA 900
AATCAAAAAA AAAAAAAAAA AAAA 924
Figure 2.5 The cDNA and protein sequence of Dnajc20
The cDNA sequence isfromRiken clone 1700030A21. ▼ illustrates the exon
boundaries of Dnajc20 Exon 4, lost through exon skipping as a result of the
Dnajc20 mutation is highlighted in red. Single line represents the J-domain,
the double line represents the C-terminal domain. The underlined CTG was
originally published as the start site.
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The Dnajc20 gene has previously been published as mmDjc7, a J-protein family member
22that encodes a type III cytosolic J-protein . The mouse family of J-proteins and their
cellular functions is discussed in detail in chapter 3, with particular reference to
Dnajc20. The mmDjc7 gene was reported to encode a 196 amino acid protein. This is in
contrast to the 148aa protein predicted by my sequencing of the exons, and the
annotation in the various databases. The authors identified an ATG in exon 1, which
they suggested as the start site. However, following the sequencing of this exon in a
number of different mouse strains, this ATG only appears to be present in the cDNA
22clone AY028460, used in the characterisation of mmDjc7 . In the other strains this
position is a CTG (thick underline in Figure 2.5) and the published start site for mmDjc7
is most likely due to a sequencing error.
2.3.2 Phenotype of the Dnajc20 homozygous mutant embryos
After the Dnajc20 mutant line was rederived in our facility, a series of crosses on to the
C3H genetic background was performed. The C3H background was used as it had been
used in the maintenance of the line at MRC Harwell and it has a number of genetic
markers that differ from the BALB/c genetic background for genotyping. The BALB/c
content of the Dnajc20 mutant line had been inherited from the mutagenised founder and
would therefore contain additional ENU induced mutations. Several generations of
crosses on to the C3H background to remove any remaining ENU induced changes that
may affect the phenotype ofDnajc20 mutants.
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The Dnajc20 mutation carriers were followed through the initial crosses through the use
of the Mit markers, distinguishing between the BALB/c background in which the
mutation was present and the C3I1 background, which was wild-type for the mutation.
However, there appears to be a recombination hotspot immediately distal of the Dnajc20
gene, which resulted in problematic typing of mutation carriers. Therefore, following
the preliminary crosses to C3H, typing performed by sequencing the ENU induced
mutation in intron 4 ofDnajc20.
Intercrosses between Dnajc20 heterozygous were performed to better characterise the
homozygous phenotype caused by the mutation, and determine the time of prenatal
death of the majority of the homozygotes. Contrary to results from MRC Harwell, no
homozygous Dnajc20 mutant mice were born in from these crosses, suggesting that the
phenotype observed is more severe on the C3H background than on a mixed
C3H/BALB/c background. To investigate the time of lethality in the Dnajc20
homozygous mutant embryos a series of intercrosses were performed, and embryos
recovered at various stages throughout embryogenesis. As a small proportion of the
homozygotes had previously been viable it was speculated that embryonic death would
most likely occur at later stages of development. At embryonic day 14 and later
homozygous embryos were recovered, however, all of these had died at earlier stages
and had begun to be resorbed (Figure 2.6.A to C). The mutant embryos at these later
stages show gross morphological abnormalities and are much smaller than their wild-
type littermates.
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Figure 2.6 Dnajc20 homozygous embryos
2 6 A to C, homozygous Dnajc20 mutant embryos (on the right in each image) with
wild-type littermates after E14.5. Mutant embryos are developmentally delayed
and are partially resorbed 2 6.D and E. Dnajc20 homozygous mutant embryo
with, 2 6.D, exencephaly and 2.6 E preaxial Polydactyly of the right hind limb
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The resorption of the embryos makes it difficult to predict the stage when the
homozygous embryos were dying, but from the visible morphology, such as the lack of
digit formation (Figure 2.6.A to C), the embryos had died (or development had arrested)
by embryonic day 13. Phenotyping of the mutant embryos is also made problematic
because of resorption. The semi-resorbed embryos are very delicate and therefore,
difficult to handle. Furthermore, it is difficult to determine the extent the mutation plays
in the phenotype compared to degeneration as a result of resorption.
At E14.5 one mutant embryo was observed with Polydactyly of its right hind limb
(Figure 2.6.D and E). This is the only time Polydactyly was observed in these breeding
experiments as no other homozygous mutant embryos reached the stage where they
developed digits. This embryo also had exencephaly, a phenotype not observed with
any other Dnajc20 homozygous mutant embryos (Figure 2.6.D). Table 2.3 shows the
numbers of Dnajc20 mutant embryos recovered at various stages of embryogenesis on
the C3H genetic background. The observed numbers of Dnajc20 mutants implies that
death of the embryos starts between E9.5 and E10.5, although a minority do survive
until later stages, however overall, the numbers obtained were low at most of the stages.
This was predominantly due to small litters on the C3H background. There was a
particularly low frequency of Dnajc20 heterozygous female progeny from crosses to
C3H making the study of the homozygous embryos from intercrosses difficult.
Attempts to replicate the phenotype seen at MRC Flarwell, and increase progeny
number, by backcrossing on to BALB/c had no immediate effect.
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Table 2.3 Dnajc20 embryos 1
Wild-type Heterozygotes Homozygotes
E8.5 3 10 3
E9.5 3 4 1
E10.5 10 15 3
Ell.5 7 12 2
E12.5 6 12 3
E13.5 10 26 5
E14.5 and above 16 36 9
Table 2.3. On a C3H background Dnajc20 homozygous mutants begin to die by E10.5. After
E13.5 the majority are only present as resorption sites.
In order to reduce the severity of the Dnajc20 homozygous phenotype, as well as
increase litter sizes to produce more heterozygous animals, the mice have recently been
crossed on to the outbred CD! background. After one generation of outbreeding,
intercrosses were performed between heterozygous littermates and the homozygous
phenotype examined from E10.5 to PI. This breeding strategy appears to initially be
giving the desired results, an increased number of mutant embryos and better survival.
Table 2.4 shows the numbers obtained from these crosses.
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Table 2.4 Dnajc20 embryos 2
Wild-type Heterozygotes Homozygotes
E10.5 2 8 10
Ell.5 3 7 3
E12.5 0 6 1
E13.5 8 17 8
E15.5 7 10 2
E16.5 3 6 1
Table 2.4. The genotypes of embryos after breeding to CD1.
The homozygous embryos are easily distinguishable by phenotype is visible from El0.5,
the earliest stage examined on this mixed background (Figure 2.7.A). Dnajc20
homozygous mutant embryos are small throughout embryonic development, are delayed
in development (Figures 2.7.A to F) and show Polydactyly (Figure 2.7.G). Figure 2.7.C
best illustrates the developmental delay. The mutant El3.5 embryo is similar in size and
development to a wild-type El2.5 embryo. The developmental delay can also be seen
by comparison of the mutant E16.5 embryo (Figure 2.6.F) with the wild-type E15.5
embryo (Figure 2.6.E).
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After E13.5 there is a significant fall in the number of expected mutant embryos. Figure
2.7.D shows a wild-type El3.5 embryo with two mutant littermates and provides
evidence for the varying severity of the Dnajc20 mutant phenotype. Both mutant
embryo are small (being similar in size to an E12.5 embryo, Figure 2.7.C) and
developmentally delayed. However the extent of development varies enormously, one
of the mutant embryos (centre in Figure 2.7.D) appears to be delayed by nearly 24 hours
in development, whereas the other mutant embryo (right in Figure 2.7.D) is delayed by
at least 48 hours in the development of the limb bud. In this embryo development seems
to have arrested, but as it is a similar size to its mutant littermate, growth appears to have
continued. It is possible to speculate that mutant embryos that are delayed by up to 24
hours may be able to survive until later stages of development, whereas the embryos
where development appears to have arrested will be lost. Dnajc20 homozygous mutant
embryos are able to survive further in development on this genetic background, and will
allow more detailed study of their embryonic postnatal phenotype. Out of 20 pups bom
from 2 litters one Dnajc20 mutant has been bom (Figure 2.8.A). This PI animal was
smaller than its wild-type and heterozygous littermates (mutant weight was 0.9g
compared to an average wild-type weight of 1.85g and heterozygote weight of 1.81 g).
The mutant animal didn't feed but was alive at birth. Figure2.8.B to D shows the small
size of the mutant internal organs compared to those of a heterozygous littermate.
Figure 2.8.E illustrates delayed development of the mutant spleen.
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Figure 2.7 Dnajc20 homzygous mutant phenotype
2.7.Ato F. Dnajc20 homozygous mutant embryos through development. 2.7.A. E10.5 wild-
type embryo (left)and two mutant E10.5 embryos (right). 2.7 B. E11.5 wild-type embryo
(left) and E11.5 mutant embryo (right). 2.7.C. E12.5 wild-type embryo (left), E13.5 wild-
type embryo (centre), and E13.5 mutant embryo (right) illustrating the developmental
delay of the mutant embryo. 2.7.D. E13.5 wild-type embryo (left), ad two E13.5 mutant
embryos (right). The embryo on the right displays severe developmental delay, but is of
similar size to the other mutant embryo. 2.7..E. E15.5 wild-type embryo (/eft) and mutant
E15.5 embryo (right). 2.7 F. Wild type E16.5 embryo (left) and mutant E16.5 embryo
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2.4 Discussion
A large number of mutagenesis screens have been performed in the mouse with the goal
of determining gene function via the effects of mutation. Our group, in collaboration
with MRC Harwell, has recently performed an ENU screen targeted against a 3Mb
region around the Pax6 gene on mouse chromosome 2. One mutation has been
identified from this screen and results, predominantly, in embryonic death around
midgestation. The homozygous embryos display growth retardation and are
developmentally delayed, with some having preaxial Polydactyly on one or both hind
limbs. By sequencing the genes present in the candidate region 1 have identified a
mutation in a gene encoding a J-protein family member of unknown function. The
mutation, a T to A transversion at position +2 of the splice donor site in intron 4 of
Dnajc20, results in the in-frame skipping of exon 4, essentially causing a 23 amino acid
deletion of the potential protein.
These findings reveal that, on the whole, Dnajc20 is necessary for embryonic and
postnatal survival. The primary phenotype of the Dnajc20 mutant homozygotes is their
universal reduction in size, as well as preaxial Polydactyly in the majority of cases.
Only three Dnajc20 mutant homozygotes have survived past weaning, and these were all
from the initial intercrosses performed at MRC Harwell. These were small compared to
wild-type and heterozygote littermates and had Polydactyly on their hindlimbs.
However, only one homozygous animal has been bom since. On a C3H background all
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of the homozygous embryos appear to die by E13.5, although some embryos can be
recovered from resorption sites at later stages. On this background there is also a
reduction in the expected number ofmutant embryos from around E10.5. The presence
of one generation of CD1 crosses to the phenotype seems to rescue a fraction of the
mutants. The majority still appear to die by E13.5, but there is now a subpopulation that
can survive until after birth. An interesting feature of the phenotype is shown in Figure
2.6.D. Here, two E13.5 mutant littermates illustrate the two phenotypic subclasses
caused by the mutation in Dnajc20. The two mutant embryos are of a similar size,
however, there is obvious developmental delay in one of them. This embryo was
removed from a resorption site and would represent the population that die by
embryonic day E13, whereas the other mutant from this litter may be able to survive
until birth. Although the numbers are small, especially in the case of the recent results
obtained by crossing to the CD1 mice, they do suggest the presence of genetic
differences between the genetic backgrounds that modify the Dnajc20 mutant
phenotype. Presence of the CD1 into the crosses will allow the more detailed
characterisation of the Dnajc20 homozygous phenotype, and the dissection of the
physiological role of the Dnajc20 protein.
An obstacle in the use of ENU mutagenesis is also one of its benefits. As ENU induces
a mutation at a rate of approximately 1 per megabase31, there is the possibility that any
base change identified may not be the mutation responsible for the phenotype. In order
to be sure that the identified mutation is indeed the cause of the phenotype further
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investigation may be needed. Techniques used include BAC rescue, whereby the wild-
type allele of the candidate gene is reintroduced to the mutant mouse to rescue the
phenotype. Having a second mutant allele in the candidate gene also allows
confirmation of the candidate. In the case of Dnajc20 there are a number of gene-trap
cell lines that disrupt the gene. We have imported one of these gene-trap lines, an
insertion in intron three that will result in the loss of the final two exons, and this will
provide definitive proof that the mutation in Dnajc20 does result in the observed
phenotype. However, even without the gene-trap mutation, there are a number of
convincing factors that the identified Dnajc20 mutation is responsible for the phenotype.
The strategy of the screen and subsequent recombination localises the mutation to a
1.4Mb region. The size of the region suggests the slight possibility of an additional
ENU induced change. However, the majority of the coding sequence of the region has
been sequenced and the only change identified was that in Dnajc20. The most striking
evidence in the verification of this mutation, however, is the phenotypic similarity to a
mutation in another gene, which is involved in the same biological process as Dnajc20
and is discussed in chapter 4.
The use of ENU mutagenesis to provide mutations in order to define protein function is
proving highly successful. Here, I have identified a mutation in a J-protein of unknown
function. The challenge now is to identify the role of Dnajc20 in a biological context.
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3.1 Introduction
The identification of a mutation in Dnajc20 resulted in an interest in this large family of
molecular chaperones. However, upon initial investigation it became apparent that the
annotation of the J-protein family has been problematic, with numerous omissions and
misannotations. A number of different nomenclatures are commonly used in describing
members of this family and this is further complicated by the some genes having
multiple names. In this chapter I have used a bioinformatics approach in the
classification of the mouse J-protein family as a basis for the further study of Dnajc20.
3.1.1 The Hsp70-chaperone machinery
The term molecular chaperone describes a wide group of unrelated protein families that
are principally responsible for preserving a functional set of cellular proteins. The
majority of molecular chaperone families are called heat shock proteins (l isps) as their
initial discovery was due to their rapid induction following stress. The Hsp70-chaperone
machinery is one of the most studied examples of molecular chaperones and is
composed of the Hsp70 proteins themselves and their co-chaperones the J-proteins.
These chaperone pairs form an abundant set of machinery that is highly conserved
53
throughout evolution and present in all biological kingdoms . IIsp70-chaperone
machines are involved in many processes in cell survival and normal cell physiology
including; 1) folding of newly synthesised proteins, 2) translocation of proteins across
46
Chapter 3 Dnaic20 and the mouse family of J-proteins
membranes, 3) transportation of proteins to their correct location, 4) assisting the
formation of protein complexes, 5) targeting proteins for degradation. In addition to
these classical roles of the Hsp70-chaperone machinery in protein folding, more
specialised regulatory roles are emerging in signalling pathways, and the maintenance of
intermediate states of protein substrates54.
3.1.2 The Hsp70 proteins
Hsp70 proteins are highly conserved and contain the same overall structure throughout
evolution. There are at least 14 Hsp70 proteins in eukaryotes55, and the conservation
between mouse Hspalb, previously named Hsp70, and E.coli DnaK, the characteristic
member of the Hsp70 protein family, is 50% identity at the protein level56. They are
made up of three domains, an N-terminal actin-like ATPase domain, the substrate
binding domain (SBD), and a C-terminal domain involved in the interaction with J-
proteins.
The mechanism of substrate recognition by the SBD is relatively non-specific. The SBD
recognises short hydrophobic segments within the substrate polypeptide, which
57
comprises 5 amino acids, Hanked by positively charged residues . It is less clear,
however, how Hsp70 proteins bind folded substrate proteins. To be identified as a
substrate a folded protein might have to contain an exposed structure, either by locally
CO
unfolding or by containing an intrinsically unfolded hydrophobic segment .
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3.1.3 The Hsp70 ATPase cycle
The activity of Hsp70 proteins is reliant upon the binding and release of ATP, which in
turn regulates the activity of the Hsp70 proteins interaction with its substrate via the
SBD59. Binding of ATP to the N-terminal ATPase domain of Hsp70 decreases the
affinity of the SBD with the substrate. Consequently, Hsp70 protein cycles between an
ATP bound state where the SBD is open, and an ADP state where the SBD is closed and
the substrate is trapped"'60 (Figure 3.1). The affinity of Hsp70 alone for ATP is minimal
and is strongly increased by J-proteins61'62. It is now accepted that the specificity of the
Hsp70-chaperone machinery is provided by the J-proteins, whereby presentation of a
substrate protein is coupled to the stimulation of ATPase activity of its Hsp70
partner54'63.
3.1.4 J-proteins
The name J-protein originates from the E.coli protein DnaJ, the prototypical member of
the family. The DnaJ gene of E.coli was originally identified because when mutated it
blocked bacteriophage X DNA replication64"66. Other mutations were shown to be
detrimental to bacterial growth at high temperature, providing the name for the gene67.
The E.coli DnaJ gene forms an operon with the DnaK gene, the bacterial homologue of
the eukaryotic Hsp70s65.
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The 37kDa DnaJ protein of E.coli is composed of four domains (Figure 3.2.A), and is
the best studied of the J-proteins. At the N-terminus of DnaJ is the J-domain, a structure
consisiting of four a-helices that is required for the stimulation of its Hsp70 protein
partner, DnaK.
Helices II and III form an antiparallel strucure seperated by an exposed loop which
contains the tripeptide Histidine-Proline-Aspartic acid (HPD) motif, all three residues of
which are essential for the stimulation of DnaK. Helices I and IV at either end of the J-
domain are less well conserved and function in stabilising the antiparallel structure of
the central helices. Adjacent to the J-domain is a region of approximately 40 amino
acids, which is rich in glycine and phenylalanine (GF) residues. This structure is
thought to act as a flexible linker region56, and is required for the maximum stimulation
ofHsp70 proteins by the J-domain68. Distal of these two domains is a cysteine rich zinc-
binding domain, which is involved in the binding of unfolded protein substrates and as
an interaction site with Hsp70 proteins69. These three domains are contained in the first
half of the protein, the second half contains the C-terminal domain (CTD) which is
poorly understood and less well conserved between different J-proteins 56.
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Figure 3.1 The Hsp70 ATPase cycle
The regulation of Hsp70 ATPase activity and substrate binding is controlled by the co-
chaperone J-protein. 1 Hsp70-ATP has low affinity for the substrate protein. 2 The J-
protein presents a substrate protein to its Hsp70 partner and stimulates its ATPase activity
resulting in 3. Hsp70-ADP with high affinity for the substrate protein. The modified substrate
protein is released, and Hsp70 returns to an ATP bound state
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A
J-domain GF Zn24 Zn24 CTD
B
J-domain GF Zn24 Zn24 CTD
J-domain GF
Figure 3.2 E.coli Dnaj and the J-protein subclasses
Adapted from Cheetham and Caplan, Cell Stress &Chaperones (1998)56.
A. The domain structure of Eco//DnaJ, an N-terminal J-domain,GF
rich region, Cysteine rich zinc binding domain, and the poorly
conserved C-terminal domain (CTD).
B. Sub-classification of the J-proteins. Type I J-proteins share full
domain structure with E.cotf DnaJ. Type II J-proteins contain an N-
terminal J-domain and the GF rich region. Type III J-proteins only
have a Jdomain in common with Eco/i'DnaJ, and this can be
anywhere within the protein.
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3.1.5 The nomenclature of the J-proteins
The J-protein family has previously been described by a number of terms including the
Hsp40 proteins, DnaJ homologues, J-domain proteins, and a variety of combinations of
these names. The term J-proteins has recently been coined to describe the large family
of molecular chaperones that contain a J-domain, defined by the presence of four helices
53and the HPD motif . This definition of the family also distinguishes the J-proteins from
the J-like proteins, which contain a domain similar to the J-domain but lack the HPD
motif. The J-like proteins, such as Paml6 in yeast70, are unable to activate the ATPase
activity of HSP70 proteins. This definition of a J-protein follows the establishment of a
sequence based classification of the J-protein family56 and a naming system that reflects
this has been suggested71. An evolved form is now in place in the higher eukaryotes.
The nomenclature of the J-protein family had previously been very complicated with
many genes having multiple names under different classification systems. Due to this,
the J-proteins discussed here will be referred to using the current J-protein nomenclature
system as well as by their other common names.
3.1.6 Sub-classification of the J-proteins
The J-protein family encompasses a diverse group of proteins with very different
domain structures, the only common feature being the J-domain. This variety led to the
classification of the J-proteins into three sub-groups based upon their overall
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conservation with E.coli DnaJ56 (Figure 3.2.A and B). In this classification system the J-
proteins, which have full domain conservation with DnaJ, are called the type I J-
proteins. Type II proteins have an N-terminal J-domain as well as the GF rich region,
and the type III J-proteins only have the J-domain in common with DnaJ, the position of
which varies within the protein.
It has been suggested that some J-proteins may have acquired the J-domain to present a
particular substrate to an Hsp70 partner, and utilise the chaperone activities for a specific
role instead of a more general chaperone function54. This type of specialised chaperone
is thought to be made up predominantly of type III J-proteins, with the type I and type II
J-proteins performing a more general chaperone function53'54. By definition, all of the
type I J-proteins contain the same domain complement as E.coli DnaJ, and are likely to
be functionally equivalent. For example, the mammalian type I J-protein Dnajal
(Hsj2/Hdj2), a partner of the constitutively expressed cytosolic Hsp70 protein Hsc70, is
required for the refolding of denatured proteins and protein import into the
mitochondria72'73. In addition to their J-domains and GF rich regions some of the type
II J-proteins contain additional domains, although these are also linked to a traditional
chaperone function, such as the ubiquitin interaction motif of the neuronally expressed
DnajblO (Hsjl). This J-protein functions in the prevention of protein aggregation and
stimulates the sorting of proteins to the proteosome74"76.
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One of the best understood examples of a type 111 J-protein system is the clathrin coat
77 80
disassembly mediated by bovine auxilin (Dnajc6) " . Auxilin is a 910 residue protein
composed of an N-terminal tensin-like domain, a central clathrin binding domain, and a
C-terminal J-domain. Auxilin binds to clathrin-coated vesicles via its clathrin binding
domain and then recruits its Hsp70 partner, Hsc70 through its J-domain. In a reaction
coupled to ATP-hydrolysis, auxilin and Hsc70 disassemble the clathrin coat to form a
transport vesicle. Interestingly other J-domain proteins have also been identified in this
process, including Cyclin G-associated kinase (GAK), which, outside of its kinase
domain shares high homology with auxilin81"83. The Drosophila orthologue of




The number of J-proteins that have been identified to date is much greater than the
number of Hsp70 proteins. For example there are 22 J-proteins in yeast compared to
only 14 Hsp70 proteins . This difference in numbers is explained by Hsp70 proteins
being able to interact with multiple J-proteins. A good example is the Hsp70 partner of
auxilin Hsc70. This Hsp70 protein is the partner of the other J-proteins involved in
clathrin dependent processes, as well as DnajclO (Hsjl)74, Dnajal (Hdj2, Hsj2)73, and
oc
Dnajc5 (Csp) . Not all Hsp70 proteins have multiple J-protein partners, for example,
86the yeast Hsp70 Sszl only interacts with the J-protein Zuol .
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The J-proteins have thus far only been shown to have one in vivo Hsp70 partner each.
Domain swapping experiments and in vitro studies have shown that some J-domains are
capable of stimulating the ATPase activity of multiple Hsp70 proteins, for example
E.coli DnaJ is capable of stimulating mammalian Hsc70 87. Dnajc20 was published as a
J-protein that is able to stimulate the ATPase activity of Hsc70, the endoplasmic
99
reticulum resident Hsp70 BiP, and E.coli DnaK . Experiments such as these suggest
that some J-proteins have the potential to stimulate multiple Hsp70 proteins, however,
additional factors such as their localisation will ultimately determine whether these
interactions occur under normal physiological conditions.
Over the past few years it has been established that the functional specificity of the
Hsp70-chaperone machinery is provided by the J-proteins, with the structurally diverse
type III J-proteins in particular being involved in a wide range of different functions.
The hypothesis that the J-domain of these type III J-proteins has been recruited to bring
chaperone power to a particular process, the other structural features of these proteins
may offer important clues in assigning a function.
3.1.8 Mutations in the mouse J-proteins
The analysis of mutations within the J-protein family has provided a wealth of
information regarding their function, and the requirements of the J-domain. The
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majority of this work was performed in E.coli DnaJ and, as stated previously, first
identified the J-proteins as molecular chaperones65. The systematic deletion of yeast
ORFs also means there is a ready made knock out of each of the yeast J-proteins, and
this resource has been used in their characterisation since the first yeast DnaJ homologue
oo
was identified . Much less is known about the effect of mutations in the J-protein
family in higher eukaryotes. Dnajc20 is only the sixth mouse J-protein which has been
mutated, and the first by ENU mutagenesis.
The first of the mouse J-proteins to be mutated in the mouse was the type II Dnajb6
(Mrj), which was identified in a gene trap screen for developmentally important genes
(Mrj)89'90. Homozygous mutants die at El8.5 due to a failure of chorioallantoic fusion.
Dnajb6 (Mrj) was shown to be expressed in the placenta and developing embryo, as well
as in some adult tissues, the early lethality precluded study of its role in these tissues.
The finding that it was required for formation of the chorioallantic placenta showed for
the first time the requirement for some J-proteins in developmental processes.
Over the past year, four more mouse J-proteins have been mutated by targetted knock
out. Mutation of the type I J-protein Dnajal (DjAl, Hsj2, Hdj2) resulted in defects in the
late stages of spermatogenesis91. Dnajal (DjAl, Hsj2, Hdj2) is widely expressed in the
mouse, but is potentially functionally redundant with Dnaja2 (DjA2, mDj3), which has
similar expression. Dnaja3 (mTid-1) is the orthologue of the Drosophila l(2)tid gene,
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Tid56, the first J-protein to be identified as a tumour supressor92. Dnaja3~'~ embryos die
between E4.5 and E7.5, due to unknown defects93.
Two type III J-proteins have also been knocked out recently, Dnajc5 (CSP), an abundant
synaptic vesicle protein94, and Dnajc3 (p58IPK), which functions in the ER stress
response95. Dnajc5~'~ animals are physiologically normal for the first two weeks of life,
however, after this time they stop gaining weight, and after P21 they begin to die due to
a progressive neurological disorder94. The neurological disorder is a result of a loss of
integrity at the neuro muscular junctions (NMJ). Mutation of the Dnajc3 gene results in
low body weight due to a decrease in the number of insulin producing P-cells in the
pancreatic islets95. The Dnajc3 protein is thought to function as an "off switch" to signal
the downregulation of ER stress proteins following their initial stress response. The
absence of the Dnajc3 protein, therefore results in the misexpression of the ER stress
proteins causing an increase in apoptosis in the P-cells.
The five mutations reported in mouse J-proteins result in a variety of phenotypes and
provide evidence of the functional diversity of the family in the higher eukaryotes, with
essential roles in development, spermatogenesis, neuroprotection, and diabetes.
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3.1.9 Dnajc20 and the mouse family of J-proteins
The J-proteins have been most intensively studied in prokaryotes, with the majority of
the functional information arising from E.coli DnaJ. This family of proteins is much
larger in the eukaryotes and the number of J-proteins identified is still increasing.
Recently, via the analysis of the Saccharomyces cerevisiae genome, Walsh et al
identified the full complement of J-proteins in a eukaryote revealing the presence of five
type I, 4 type II, and 13 type III J-proteins53.
A number of the individual mouse J-proteins have been well studied including Dnajal
(Hsj2, Hdj2)72, DnajblO (Hsjl)96, Dnajc5 (Csp)97, and Dnajc3 (p58IPK)95. However, as
a family they remain complicated with a number of omissions and misannotations.
Previous studies have revealed the presence of at least 23 J-proteins in the mouse,
however, the total number has yet to be determined71. The MGI database
(http ://www. informatics. iax .org) currently lists 39 J-proteins under the accepted
nomenclature, whereas, the Ensembl database (http://www.ensembl.oru) suggests the
presence of 51 J-proteins, based upon the presence of an INTERPRO J-domain. The
Dnajc20 protein is identifiable in the Ensembl database by the presence of the
INTERPRO definition of the J-domain, but is absent from the list of J-proteins in the
MGI database. In order to properly relate the Dnajc20 protein to the other J-proteins, the
starting point has to be the correct organisation of the mouse J-protein family.
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3.2 Results
3.2.1 Identifying the J-protein family members in mouse
Due to the complicated appearance of the J-protein family in mouse, 1 decided to use a
bioinformatic approach to clarify the situation and potentially confirm the presence of
novel J-proteins. The genuine number of J-proteins in the mouse is difficult to gauge,
the MGI database currently lists 39 J-proteins under the official nomenclature, and in
Ensembl, the Heat shock protein DnaJ N-terminal INTERPRO domain (IPR001623) is
annotated as being present at 51 loci (http://www.ensembl.org/Mus musculus
/domainview?domainentry=TPROO 16231. However, neither of these two databases
reflect the true number J-proteins in mouse. The MGI database is likely to contain all of
the J-proteins but if they are not named according to the current nomenclature, they will
be omitted from the family. In a number of cases, the presence of a J-domain in
Ensembl does not correspond to a functional ORE. Additionally, the INTERPRO
annotation of a J-domain is not very stringent, and therefore includes a number of
proteins that would fall into the category of J-like proteins. However, by using a
combination of the information in the MGI database, the presence of the 1PR001623
entry in Ensembl, and information in the literature, I have been able to construct a list of
genuine J-proteins encoded by the mouse genome as defined by the presence of a J-
domain. The J-domain was confirmed by SMART analysis (http://smart.embl-
heidelberg.de), as defined by a search with the Pfam HMMER model of the domain, and
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its postion within each protein is noted within the tables. Additional domains, identified
by SMART analysis or from information in the literature were also recorded, providing
an insight into the diverse variety of structural features present within the J-protein
family in mouse.
This analysis has revealed the presence of 48 genuine J-proteins encoded by the mouse
genome, 4 of which are type 1 (Table 1), 12 are type II (Table 2), and 32 are type III
(Table 3). This may not represent the complete number of J-proteins as the presence of
additional potentially expressed sequences, that could encode J-domains within the
mouse genome leaves the possibility of further J-proteins. For example, the recently
published GyglO protein of humans has alternative 5 prime exon which encodes a J-
98domain . I could not identify an orthologue of this exon in mouse, however, the
alternative splicing of a J-domain encoding sequence onto another transcript may occur
elsewhere. Under these circumstances the annotation may be poor with the correct
transcripts not being annotated in Ensembl, especially if they belong to a poorly
expressed splice variants. To confirm the true number of J-proteins in the mouse further
work would have to be undertaken in order to confirm the expression of all of the
potentially encoded J-domains.
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3.2.2 The Mouse J-proteins
Table 1. Type I J-proteins
Gene Ensembl Gene ID Length (J- Other Domains
(alternative) domain)
Dnajal (Hsj2, Nedd7) ENSMUSG00000028410 397 (6-68) None
Dnaja2 (mDj3) ENSMUSG00000031701 412 (8-70) None
Dnaja3 (mTid-1) ENSMUSG00000004069 480 (93-158) None
Dnaja4 (mmDjA4, Hsj4) ENSMUSG00000032285 397 (6-68) None
Table 2. Type II J-proteins
Gene Ensembl Gene ID Length (J - Other Domains
(alternative) domain)
Dnajbl (Hsp40, Hdjl) ENSMUSG00000005483 340 (4-68) None
Dnajb3 (Hsj3, Msjl) ENSMUSG00000048591 242 (3-69) None
Dnajb4 ENSMUSG00000028035 337 (4-68) None
Dnajb5 (Hsc40) ENSMUSG00000036052 348 (4-68) None
Dnajb6 (Mrj) ENSMUSG00000029131 242 (3-69) None
Dnajb7 (mDj5) ENSMUSG00000047108 220(2-61) None
Dnajb8 (mDj6) ENSMUSG00000048206 227 (3-69) None
Dnajb9 (Erdj4, Mdgl, ENSMUSG00000014905 222 (26-90) Transmembrane
mDj7)
DnajblO (Hsjl,mDj8) ENSMUSG00000026203 259 (3-69) UIM (Ubiquitin
interaction motif)
Dnajbl 1 (Erdj3) ENSMUSG00000004460 358 (25-90) Transmembrane
Dnajbl 2 ENSMUSG00000020109 376 (111-175) Transmembrane
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Table 3. Type III J-proteins
Gene Ensembl Gene ID Length (J - Other Domains
(alternative) domain)
Dnaj c 1 (Erdj 1, Mtj 1, ENSMUSG00000026740 552 (61-125) Transmembrane,
Dnaj 11) SANT domain
Dnajc2 (Midal, Zrfl, Zrf2) ENSMUSG00000029014 621 (88-161) SANT domain
Dnajc3 (p581|,,c) ENSMUSG00000022136 504 (394-462) Tetratricopeptide
Repeat
Dnajc4 (Hspf, Mcgl8) ENSMUSG00000024963 244 (37-102) Transmembrane
Dnajc5 (Csp) ENSMUSG00000000826 198 (15-80) Cysteine string (CS)
Dnajc5(3 ENSMUSG00000027606 199 (19-84) Transmembrane (CS)
Dnajc5y ENSMUSG00000053856 165 (17-82) CS
Dnajc6 (auxilin) ENSMUSG00000028528 938 (874-838) PTEN clathrin
binding
Dnajc7 (mDj 1 l,mTpr2, ENSMUSG00000014195 494 (381-451) Tetratricopeptide
Ttc2) Repeat
Dnaj c 8 ENSMUSG00000054405 292 (57-123) Bipartite nuclear
localisation signal
Dnajc9 ENSMUSG00000021811 259 (15-82) None
DnajclO (Jpd 1) ENSMUSG00000027006 793 (35-100) Thioredoxin
Dnajcl 1 ENSMUSG00000039768 559 (14-82) None
Dnajcl2 (Jdpl) ENSMUSG00000036764 198 (14-79) None
Dnajcl3 (Rme8) ENSMUSG00000032560 2152 (1210- tRNA synthetase
1274)
Dnajcl4(Drip78, Hdj3, ENSMUSG00000025354 703 (444-508) Bipartite nuclear
Lip6) localisation signal
Dnajcl5 (Dnajdl) ENSMUSG00000022013 149 (94-147) None
Dnajcl 6 ENSMUSG00000040697 820 (77-141) None
Dnajcl 7 ENSMUSG00000034278 303 (11-76) RNA Recognition
Motif
Dnajcl 8 ENSMUSG00000024350 357 (82-146) None
Dnajcl9 (Dnajd2) ENSMUSG00000057330 116(62-115) Transmembrane
Dnaic20 ENSMUSG00000027166 148 (10-81) CSL zinc finger
(1700030A21Rik, mmdjc7)
493046 lP20Rik(Dnaja5) ENSMUSG00000044224 531 (3-69) C2H2 zinc finger
GAK (auxilin2) ENSMUSG00000062234 1,305 (1231- Protein Kinase,
1305) PTEN clathrin
binding
Hsc20 mouse (Hscb) ENSMUSG00000043510 234 (155-229) None
Sec63-like ENSMUSG00000019802 760 (104-165) Transmembrane
RBJ ENSMUSG00000020657 273 (217-273 RAS-transforming
Sacsin ENSMUSG00000037545 3830 (3557- Heparin, N-terminal
3644) Hsp90 like
Wbscrl 8 ENSMUSG00000063758 219(42-107) None
4930503B20Rik ENSMUSG00000048652 234 (3-69) None
2819451A06Rik ENSMUSG00000038009 339 (277-339) Transmembrane
ORF28 ENSMUSG00000039763 385 (48-113) None
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Elsewhere in this analysis certain misannotations became clear. The Dnajbl3 protein
(MGI: 1916637) has been omitted as it does not contain the HPD motif, and would
therefore presumably be unable to stimulate the ATPase activity of an HSP70 protein.
There is also no Dnajb2 protein in mouse, with the orthologue of human Dnajb2 being
mouse DnajblO (Hsjl), and conversely, there is no DnajblO in humans. The
4930461P20Rik is the orthologue of the recently published human J-protein Dnaja5,
however, this protein does not contain a GF repeat and should be included in the type III
family. 4930461P20Rik is a 531 amino acid protein with an N-terminal J-domain and a
C-terminal C2H2 zinc finger. The authors probably classified the human Dnaja5 as a
type I protein due to the presence of this zinc finger domain, but it is not homologous to
the cysteine rich zinc finger ofE.coli DnaJ99. A BLAST search with this protein reveals
53it to be the sequence orthologue of the type III yeast protein JJJ1 .
3.2.2 Bioinformatic characterisation of novel J-proteins
All of the type I and type II J-proteins have been named under the proper nomenclature,
however, 11 of the type III proteins are either unnamed or named under other criteria.
Four of these J-proteins, Wbscrl8, 4930503B20Rik, 2819451 A06Rik, and ORF28, are
novel J-proteins, although, Wbscrl8 and ORF28 have previously been identified in large
scale investigations into the content of the Williams-Beuren syndrome candidate region
in humans100, and the mouse orthologues of human chromosome 21 genes101
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respectively. It was decided to investigate these novel J-proteins further through initial
bioinformatic characterisation.
4930503B20Rik
The 234 amino acid 4930503B20Rik protein has an N-terminal J-domain, but the
remaining sequence shows no homology to any other domains. It has been identified as a
transcript that is preferentially expressed in mammalian testis by SAGE analysis. It has
orthologues by sequence in mammals, however, there is no annotated human orthologue
in Ensembl. There is a human EST from testis, AY604569, that maps to the syntenic
region. 4930503B20Rik is annotated as being a mitochondrial protein, however, this
annotation appears to be due to its homology to yeast Ydjl. PSORT II analysis
(http://psort.nibb.ac.ip/) predicts a nuclear localisation.
2810451 A06Rik
2810451A06Rik is a 339 amino acid protein with a C-terminal J-domain, SMART
analysis predicts 4 transmembrane domains and an N-terminal signal peptide. PSORT II
analysis predicts three of these transmembrane regions with high confidence and the
fourth with low confidence as well as a signal peptide, with a potential cleavage site
between residues 44 and 45. It is predicted to be an ER resident protein. The
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281045 lA06Rik gene seems to be widely expressed with ESTs being present for a
number of tissues including the lung, liver, kidney, and skin (Unigene entry Mm.30544).
2810451A06Rik has apparent orthologues in all of the higher eukaryotes by reciprocal
BLAST, and is syntenic in the mammalian genomes. Its orthologue in Drosophila
melanogaster is the tracheal system development gene wurst (Flybase entry
FBGN0030805). The wurst gene is expressed in tracheal cells from embryonic day 14
until the end of embryogenesis, as well as in other ectodermal tissues. Mutations in




ORF28 is a 385 amino acid protein with a J-domain towards its N-terminal. PSORT II
predicts that C16orf28 may be located at the mitochondria with a potential signal
sequence over the first 25 amino acids of the protein, with a possible cleavage site
between residues 25 and 26. It has orthologues down to Drosophila by reciprocal
BLAST searches. The Orf28 gene was studied as part of an investigation of mouse
orthologues of human chromosome 21 genes 101. RT-PCR and in situ hybridisation
analysis suggest that it is has low expression in the embryonic brain, branchial arch and
otic vesicle (these results are available on its MGI datasheet accession ID: 2181053).
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Wbscr18
Wbscrl8 is a 219 amino acid type III J-protein, with its J-domain being towards its N-
terminal. Reciprocal BLAST analysis reveals that the Wbscrl8 protein is conserved
down to Drosophila. It appears to be widely expressed with ESTs in multiple organs
(Unigene Mm.178012). No additional domains were identified through SMART
analysis, however, PSORT II predicts a potential transmembrane domain at the C-
terminal of the transcript, as well as a cytoplasmic localisation.
3.2.3 The mouse family of J-proteins
This analysis has provided a starting point for the study of the J-proteins in mouse and
allows a number of observations regarding the diversity of the family to be made. The
majority of the type I and type II J-proteins are of a similar size with the J-domain at
their N-terminal. The type III J-proteins, however, show a massive size difference with
the smallest, Dnajcl9, being 116 amino acids and the largest, Sacsin, being 3830 amino
acids. The position of the J-domain in these type III proteins also varies and can be
present anywhere within the protein.
The SMART analysis of each of these J-proteins revealed a number of additional
domains, providing an insight into diverse structural features of this family of molecular
chaperones. The majority of these additional domains are present within the type III J-
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proteins (Table 3), and include the Myb_DNA binding SANT domains in Dnajcl (Mtjl)
and Dnajc2 (Zrfl, Midal), the cysteine string region of the Dnajc5 group of proteins, the
clathrin binding domain of Dnajc6 (auxilin), and the zinc fingers of Dnajc20 and
493046 lP20Rik.
Figure 3.3.A shows an alignment of all the J-domains from the J-proteins in mouse as
well as that from E.coli DnaJ. The positions of the structural features of the J-domain
are also included. This analysis supports previous conclusions concerning the
conservation of the J-domain in the different sub-types of J-proteins, the type I and type
II proteins have greater overall conservation than the type III proteins. This lack of
conservation is most pronounced in the loop region of the J-domain, where, in the type
III proteins it is generally greater in length and contains a wider variety of of types of
amino acid. This is particular true of Dnajc20, which has the longest loop region of the
mouse J-proteins, which comprises of 20 residues. The four helices are reasonably well
conserved throughout all of the mouse J-proteins, with helix 2 the most conserved.
There are individual J-proteins that are more divergent, such as Sacsin, which has a
smaller than average predicted J-domain and is divergent in helices 1 and 3, as well as
having a gap in helix 2. The functional relevance of these more divergent J-proteins
would require further study in order to test their ability to stimulate the ATPase activity
of Hsp70 proteins, but might provide useful information regarding the required features
of all the J-domains.
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Helix 1 Helix 2 Loop Helix 3 Helix 4
Figure 3.3 Alignment of the mouse J-proteins
An alignment of all of the J-proteins identified in mouse. The structure of the domain is
depicted at the base of the alignment. * indicates the Dnajc20 sequence.
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3.2.4 The Dnajc20 protein is conserved throughout eukaryotes
Figure 3.4 shows an alignment of the Dnajc20 protein from various eukaryotes.
Dnajc20 is most highly conserved in the higher eukaryotes, with 94% similarity between
the human and mouse proteins. However, normal BLAST searches fail to identify the
sequence orthologues from the lower eukaryotes. The yeast orthologue of Dnajc20, JJJ3
(YJR097w), shares only 27% identity with the mouse protein over their whole length.
Using the more sensitive Position-specific iterated and pattern-hit annotated BLAST
search facility identified the more distant eukaryotic orthologues by 3 iterations. The
conservation in Dnajc20 and its orthologues is highest in the N-terminal J-domain and in
a C-terminal domain. Surprisingly, the loop region of the J-domain, which is a defining
difference between Dnajc20 and the J-domains of the other mouse J-proteins, shares
little conservation across the different eukaryotic Dnajc20 proteins (Figure 3.4.A).
There is high conservation in this region between mouse and human, and to some extent
down to zebrafish. However, the length of the loop is reasonably conserved between all
of the species. The loop region of Drosophila CG2911 is the same length as that of the
vertebrates, and in the other lower eukaryotes the loop is above average in length.
Therefore, the length of the loop may be more important than its amino acid content in a
functional context.
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An alignment of the Dnajc20 protein in eukaryotes (mm, Mus musculus. hs.
Homo sapiens, dr Danio rerio. Dm Drosophila melanogaster. At. Arabidopsis
thaliana. Sc. Saccharomyces cerevisiae. Ce Caenorhabditis elegans.
An aligment of the C-terminal of mouse Dnajc20, its orthologues in humans
and yeast, and the homologous proteins from the three species.
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3.2.5 The C-terminal domain of Dnajc20
The presence of specific substrate binding domains in some of the type III J-proteins
provides important information concerning the functional roles of these co-chaperones.
The conservation of the C-terminal region ofDnajc20 across the eukaryotes, particularly
the presence of the four cysteine residues (positions 114, 116, 135 and 138 in mouse
Dnajc20), suggested that there was a conserved structure in this region, a feature which
may be functionally relevant. BLAST search analysis identified an homologous
sequence to this C-terminal domain in another protein (Figure 3.4.B). The mouse
version of this novel protein is 82 amino acids in length, and is essentially the C-
terminal region of mouse Dnajc20. It is conserved throughout eukaryotes, with one
copy being present in each species except humans. The human genome appears to
contain two such sequences, a three exon gene on chromosome 3, and a one exon gene
on chromosome 20. The chromosome 20 gene, however, is annotated as being
expressed on the opposite strand to exon 1 of the gene Tcfl5. The high conservation
between the two human copies suggests there has been a recent duplication, and the
chromosome 20 copy is a putative pseudogene.
After the identification of the C-terminal region of Dnajc20, and its homology to another
eukaryotic protein, the domain became annotated in the Pfam database
(http://www.sanger.ac.uk/Software/Pfam/"). It was annotated as a zinc finger CSL
7!
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domain, with the proteins that contain it becoming the zf-CSL family. The domain is
named because of the motif at the final cysteine. Following this annotation, the proteins
in the higher eukaryotes became named, in some databases, as Zcsll to 3. The Zcsl3
protein is Dnajc20, Zcsl2 is the homologous protein, and Zcsll corresponds to the
potential pseudogene in humans. The presence of a defined domain adjacent to the J-
domain of Dnajc20 has the potential to offer clues regarding function, in a similar way
to the other type III J-proteins with specific substrate binding domains such as Dnajc6
(auxilin). At the time of this annotation only Dnajc20 had been published, and this was
concerned with the J-domain. However, over the past two years a number of reports
have suggested roles for this domain in a variety of processes, and these will be
discussed later.
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3.3 Discussion
3.3.1 Dnajc20 and the mouse family of J-proteins
The number of identified eukaryotic J-proteins is rapidly expanding. Recently, Walsh et
al showed the presence of 22 J-proteins in yeast, making it the first eukaryote to have its
full complement of this family of molecular chaperones identified53. However, the J-
protein family in mouse is complicated by a difficult history of nomenclature, resulting
in numerous names for the same proteins, misannotations and omissions. By using a
bioinformatic approach I have analysed all of the proteins annotated as containing a J-
domain, and have been able to produce a more definitive list of the J-proteins present in
the mouse. This analysis has revealed the presence of at least 48 genuine J-proteins,
which represents the most conclusive list of J-proteins in a higher eukaryote.
Furthermore, this work has revealed the presence of 4 novel mouse J-proteins, and
allows the proper characterisation of the Dnajc20 proteins position within the family.
The identification of 48 J-proteins in mouse shows there has been a large expansion of
the family in higher eukaryotes. This expansion is restricted to the type II proteins, 12 in
mouse compared to 4 in yeast, and the type the type III proteins, 32 compared to 13. In
the case of the type I J-proteins, yeast has 5 compared to the 4 in mouse. This difference
is probaby due to the fact that two of these type I proteins in yeast, Ydj 1 and Xdj 1, have
high sequence homology and may have similar roles in vivo53. The large increase in the
type II and type III proteins could be due to gene duplications leading to more J-proteins
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having analagous functions, or by other proteins co-opting a J-domain and recruiting
chaperone power to a novel process. The most likely explanation is a combination of
both of these mechanisms. For instance, mouse Dnajc6 (auxilin), the mouse orthologue
of yeast Swa2, has high homology over most of its sequence with another J-protein
GAK. The GAK protein, which has been shown to have a similar function to Dnajc681,
is the likely product of a duplication of Dnajc6 followed by the acquisition of a protein
kinase domain at its N-terminal. The Dnajc5 (Csp) protein, and its homologues Dnajc5p
and Dnajc5y, do not have have yeast orthologues. These proteins will have evolved
after divergence from yeast, and have recruited chaperone power to their role in
neurotransmitter release.
The J-domains of these 48 mouse proteins support previous conclusions concerning
domain conservation and evolution. The type I and type II proteins show greater
conservation in the J-domain than the type III proteins. The reasons for this are
generally thought to be the closer evolutionary relationship between the type I and type
II proteins, and their need to maintain a functional partnership with their Hsp70
partner103.
The type III J-proteins overall are most divergent in the loop region of the J-domain,
where the length is generally greater and there is a greater variety of amino acid types.
This is particularly true in Dnajc20, which has the longest loop region within the mouse
J-protein family. The length of the loop region is similar in Dnajc20 and its orthologues,
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but shows little conservation from the higher eukaryotes down to yeast. The general
explanation for the divergence of the J-domain in the type 111 J-proteins is their
evolution. In the J-proteins that have formed from gene duplication there may have been
little pressure to maintain the conservation of the J-domain, due to a likely redundancy
with their progenitor103. This is probably true for those J-proteins with no functional
specificity, however, in the instances where it seems that a J-domain has been co-opted
into bringing chaperone power to a novel process, probably via recombination events,
the maintenance of a functional J-domain would be beneficial. The in vitro ability of
22
Dnajc20 to stimulate the Hsp70 activity of multiple Hsp70 proteins , and the in vivo
ability of the J-domain of Dnajc3 (p581PK) to substitute for the J-domain of yeast Ydjl
and E.coli Dnaj104, shows that some type III proteins are potentially non-specific in
Hsp70 partner choice. A low level of preference for Hsp70 partner in the type III J-
proteins might even be expected. If these J-proteins have gained a J-domain by some
genetic event, and inherited chaperone power, the Hsp70 partner available might not be
the Hsp70 partner to which the J-domain was originally intended. Therefore, there
would be room for variation within the J-domain in order to optimise its interaction with
a new Hsp70 partner. Recently, Hennessy et al suggested a model whereby helices 2
and 3 of the J-domain contact the ATPase domain of Hsp70105. This would explain the
higher level of conservation in these two regions compared to the loop region, and why
mutation in the loop is seemingly tolerated. As the loop region is between helices 2 and
3, mutations here may have a smaller effect the interaction with an Hsp70 protein to
lesser extent, and may act to modify the association. This may be an effective
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mechanism for the J-domain of the type III J-proteins to optimise there interaction with,
an essentially novel, Hsp70 partner.
3.3.2 The C-terminal domain of Dnajc20
The presence of specific substrate binding domains in the type III J-proteins such as
Dnajc6 (auxilin), the cysteine string proteins, and Dnajc3 (p58IPIi), led to the suggestion
that other J-proteins may have specialised regions outside of their J-domains that define
their function54. At the start of this project BLAST searches with the mouse Dnajc20
protein sequence revealed apparent sequence orthologues throughout eukaryotes, which
all shared homology in the J-domain as well as in a Cysteine rich region in the C-
terminal of the protein. This C-terminal domain of Dnajc20 subsequently became
annotated as the zinc finger CSL domain, which defines a family of proteins called the
zf-CSLs. The zf-CSL domain is present in two proteins in mouse, Dnajc20 and the 82
amino acid Zcsl2. Both are conserved throughout eukaryotic evolution. At the time of
this annotation, however, nothing was known concerning the function of the domain in
either Dnajc20 and its orthologues or in the small zf-CSL proteins.
The hypothesis that type III J-proteins have evolved by co-opting a J-domain, and
therefore chaperone power, to a novel situation suggests that the function of Dnajc20
will be defined by the zf-CSL domain. Over the past three years a number of reports
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have identified a potential role for the zf-CSL domain in multiple functional contexts,
including transcription, translation and secretion.
The first evidence regarding the cellular function of the zf-CSL domain was the
identification of YBL071w-a, the small zf-CSL protein of yeast, as Ktill, one of a
number of factors conferring sensitivity to the Kluveromyces lactis toxin zymocin106.
The kti (ATiller toxin insensitive) mutations result in the tot (/arget of toxin) phenotype,
107 108
which includes resistance to zymocin ' . Several of the TOT genes encode members
of the Elongator complex107, including the yeast orthologue of mammalian Elp4, the
gene adjacent to Pax6 on mouse chromosome 2109. The Elongator complex was initially
identified because of its association with hyperphosphorylated RNA polymerase 11
(RNA pol II)110. Elongator possesses histone acetyltransferase (HAT) activity, provided
by Elp3, and is thought to facilitate the elongation phase of transcription1"'112. The
human Elongator complex has also been purified and shown to have HAT activity and
the in vitro ability to interact directly with RNA pol II113. Interestingly, the human
orthologue of yeast Elpl was shown to be the 1KAP protein. Mutations in 1KAP result
in the human disease familial dysautonomia, providing a link between Elongator and
human disease114'115.
Biochemical studies have shown that Ktill is able to directly interact with Elpl, Elp2,
and Elp3, leading to the suggestion that KTI11 may mediate the association of Elongator
with the transcription machinery106'116. Loss of the Ktill protein results in the
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accumulation of a truncated form of Elpl that cannot enter the nucleus116. However, a
transcriptional role for the Elongator complex has regularly been questioned. Some
reports have failed to identify an association between Elongator and the transcription
machinery117'118, with the subunits having predominantly cytoplasmic localisation117.
Recently, a novel function for the Elongator complex has been suggested in the
regulation of polarised cell-surface transport119. The yeast Sec2 protein is a guanine
nucleotide exchange factor required for activation of the Rab GTPase Sec4, involved in
polarised cell surface trafficking of post-Golgi secretory vesicles. The Elpl protein was
shown to directly interact with Sec2 and is required for its correct localisation.
Furthermore, Rahl et al gave more conclusive evidence that Elpl does not enter the
nucleus119. Previous studies had suggested that the localisation of the Elongator subunits
was cytoplasmic, however, they could not rule out nuclear shuttling. Rahl et al used a
cell line deficient in nuclear export, therefore, any Elpl shuttling into the nucleus would
be unable to return to the cytoplasm, however, no nuclear localisation was observed.
The authors note that it is still possible that under certain unknown conditions Elpl may
localise to the nucleus.
The identification that Elongator may function in secretion supports previous findings
regarding the human orthologue of Ktill. A yeast two-hybrid screen for proteins that
interact with DelGEF (deafness locus putative guanine nucleotide exchange factor)
identified the small human zf-CSL protein (Zcsl2) and it was named DelGlPl (for
DelGef interacting proteinl)120. The DelGEF protein, like Sec2 a guanine nucleotide
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exchange factor, is associated with the human orthologue of yeast Sec5, a subunit of the
121
Sec6/8 multiprotein secretion complex . Downregulation of DelGIPl in HeLa cells
resulted in the increased secretion of proteoglycans, thus suggesting a potential role for
120
the zf-CSL domain in secretion .
It is unclear whether the identified role for the small human zf-CSL protein DelGIPl is
directly linked to the apparent function of Elongator in secretion. However, both appear
to negatively regulate the localisation of guanine nucleotide exchange factors. The
findings of Rahl et a/119, and the previous work by Krogan118 and Pokholok117 contrasts
starkly with good evidence that suggests Elongator, and therefore Ktill, are required to
facilitate RNA pol II transcription. Further work is required to clarify the biological role
of the Elongator complex before its association with the zf-CSL domain can properly be
elucidated.
The most clear-cut evidence for a biological role of the zf-CSL domain comes from two
recent papers by Liu et a/122'23. Firstly, the use of retroviral insertional mutagenesis
identified a role for the small zf-CSL protein in the synthesis of diphthamide, the target
of bacterial ADP-ribosylating diphtheria toxin and Pseudomanas exotoxin A24'124.
Secondly, the study of the diphthamide biosynthesis pathway in yeast identified a
requirement for both the small zf-CSL protein and the yeast orthologue of Dnajc202j.
This work is discussed in detail in the next chapter and forms the basis for the
investigation of a cellular role for mouse Dnajc20.
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4.1 Introduction
Diphthamide is a post-translational modification unique to translation elongation factor
2 (eEF2), and is the target of the ADP-ribosylating diphtheria toxin (DT) and
Pseudomonas exotoxin A (ETA)24'124. Although it is 25 years since diphthamide was
identified its function in normal cell physiology is still unknown. Mutations in yeast and
CHO cells were generated around 20 years ago that fail to make diphthamide, however,
it is only in the past year that all of the proteins have been identified125"127. Analysis of
both the yeast and CHO mutant cells has revealed the requirement of both the small zf-
CSL protein (Dph3/Ktil l/YBL071w-a in yeast and DESR1 in CHO cells), and the yeast
orthologue ofmouse Dnajc20 in diphthamide biosynthesis (JJJ3/YJR097w).
4.1.1 DT and ETA inhibit protein synthesis
Diphtheria toxin (DT) and Pseudomonas exotoxin A (ETA) belong to the family of
ADP-ribosylating toxins that includes cholera, pertussis and the C2 and C3 toxins of
Clostridium botulinum. These toxins catalyse the transfer of ADP-ribose from NAD+
onto a target protein, and result in the disruption of various metabolic processes within
the host cell. Although the action of this family of toxins is the same, the target varies;
the Clostridium C2 toxin target is G-actin, the C3 toxin target is Rho, and the cholera
and pertussis toxin targets are the G-proteins. The target of both DT and ETA is the
I ?R
translation protein eEF2, specifically the modified histidine residue diphthamide . The
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eEF2 protein is essential for polypeptide elongation in protein synthesis, forming a
complex with GTP and the ribosomes and catalysing the GTP dependent translocation of
peptidyl-tRNA from the aminoacyl (A) site to the peptidyl (P) site on the ribosome
(Figure 4.1). The GTP binding domain is at the N-terminal end of eEF2 and the
interaction with the ribosome is towards the C-terminus. The DT and ETA toxins bind
to the same region of eEF2 as the ribosomes and catalyse the transfer of ADP-ribose
from NAD to the diphthamide residue, inactivating eEF2 and causing a lethal blockage
in protein synthesis24.
4.1.2 Diphthamide biosynthesis
The diphthamide modification is present in all eukaryotic organisms, where it is
1 99
restricted to a histidme residue of eEF2 (position 715 in mammals and 699 in yeast) .
There is also evidence of a diphthamide modification, or a precursor of diphthamide in
the analogous elongation factor of archaebacteria130. However, it is absent from EF-G,
the eubacterial orthologue of eukaryotic eEF2. Therefore, DT and ETA are specific for
the eukaryotic, and perhaps archaebacterial, protein synthetic machinery, but do not
target the elongation factor of the pathogens that produce them. Even though it is over
25 years since diphthamide was identified little is known about its function.
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Figure4.1 Translation elongation is inhibited by DT and ETA
(Adapted from http://nobelprize.Org/chemistrv/educational/dna/a/translation/elonQation.html)
eEF2 catalyses the translocation of peptidyll-tRNA from the A site to the P-site in a GTP
dependent process in the final step of translational elongation. DT and ETA bind to the
region of eEF2 that interacts with the ribosome and catalyse the addition of an ADP-ribose
moiety to the diphthamide residue This removes the ability of eEF2 to interact with the
ribosome, inhibiting protein synthesis.
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Diphthamide deficient mutations have been generated in yeast127 and CHO cells125 by
chemical mutagenesis and selected due to their resistance to diphtheria toxin. The
mutations fall into 5 complementation groups in yeast termed Dphl, Dph2, Dph3, Dph4,
and Dph5127, and 4 in CHO cells termed CG-1, CG-2, CG-3, and CG-423'125. However,
the mutant cells, grow at a normal rate and display no obvious phenotypes besides toxin
resistance126'127.
The identification of mutations defective in diphthamide biosynthesis has allowed
genetic analysis of the pathway, and revealed it to be one of the most complicated post-
122translational modifications identified . Figure 4.2 illustrates the diphthamide
biosynthesis pathway, and the steps affected by each of the yeast and CHO
23 125 127
complementation groups ' ' . The first step involves the transfer of a 3-amino-3-
carboxypropyl moiety from S-adenosylmethionine (AdoMet) to the C-2 imidazole of the
target histidine to produce an intermediate structure, and requires Dphl to 4 and CG-2 to
4. Subsequently, trimethylation of the intermediate modification by an AdoMet-
1 31
dependent methyltransferase to produces diphthine, a process requiring Dph5/CG-1
l33. The final step is the amidation of the side chain carboxyl group of diphthine by an
ATP-dependent enzyme resulting in diphthamide. No mutations have been identified in
this final step as diphthine can also be ADP-ribosylated, although at a slower rate than
diphthamide126, and an ATP-dependent amidation enzyme is still to be identified23.
Finally, DT and ETA are able to ADP-ribosylate diphthamide at position C-3 of the
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The Dph2 protein, consisting of 594 amino acids with no known domains, and AdoMet-
dependent methyltransferase Dph5 protein were identified by Mattheakis et al over 10
years ago132'134. However, it is only in the last two years that the proteins mutated in the
remaining complementation groups have been identified. Using retroviral insertional
mutagenesis, a DT and ETA resistant CHO cell line was identified. The mutated gene
encoded the small zf-CSL protein and was named DESR1, for DT and ETA sensitivity
required l135. The mutation was shown to correspond to the original CG-2 CHO cell
complementation group. Subsequently, the orthologous gene in yeast, Ktil 1/YBL07 lw-
a was identified as the Dph3 mutation23.
Transposon mediated mutagenesis was used in the identification of the remaining yeast
Dph mutations23. Transposon mutagenesis allows the easy identification of the mutated
genes by sequencing the transposon insertion site, compared to the original chemically
generated mutations, which require mapping. Following selection of DT resistant
strains, complementation testing against the original Dph mutant strains was performed.
The Dphl protein was identified as YIL103w a 425 amino acid protein that shares 49%
homology with Dph223. The mammalian orthologue corresponds to the CG-4
9 3
complementation group in CHO cells . Dphl and Dph2 were shown to interact by co-
immunoprecipitation. Interestingly there is an archael orthologue of the Dphl/Dph2
i / o
proteins, which might represent ancient evolutionary conservation of the pathway .
The Dph4 mutation was identified as JJJ3/YJR097w, the yeast orthologue of
23mammalian Dnajc20 . However, there is no corresponding CHO cell mutation.
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The mechanism of how the Dphl to 4 proteins function in the first step of diphthamide
biosynthesis is unknown. The presence of multiple proteins in the first step of the
diphthamide biosynthesis pathway led to the suggestion that they may function as part of
132
a multiprotein complex . This is supported by high-throughput yeast two-hybrid
screens in both yeast and Drosophila, which show interactions between Dphl and Dph2,
and the co-immunoprecipitation experiments showing interactions between yeast Dphl
and Dph2, and mouse Dph 1 and Dph2. Furthermore, recent work in yeast has identified
that Dph3/Ktil l/YBL071w-a can bind eEF2, Dphl and Dph2, as well as ribosomal
proteins Rps7a and Rpsl9a136. However, as the yeast J-protein, Dph4/JJJ3/YJR097w,
was not detected as a Dph3/Ktil l/YBL071w-a interactor in the same assay, it has been
suggested that it either acts separately to the other Dph proteins, or indirectly on the first
step of diphthamide biosynthesis23. However, as Dph3/Kti l 1/YBL071 w-a contains little
more than the zf-CSL domain, which is shared with Dph4/JJJ3/YJR097w, it is possible
that both proteins share the same interactors, but are required at different times.
The identification of JJJ3/YJR097w as Dph4 and its requirement for diphthamide
biosynthesis strongly suggested that Dnajc20, its mouse orthologue, may function in the
same process and that the Dnajc20 mutant phenotype is due to a deficiency in
diphthamide biosynthesis and protein synthesis.
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4.2 Results
4.2.1 Dnajc20 Antibody Production
To characterise the function ofDnajc20 and its role in diphthamide biosynthesis a rabbit
polyclonal antibody was raised against bacterially expressed full-length Dnajc20. The
coding region of Dnajc20 was amplified by RT-PCR using primers engineered with
Xbal and Hindlll restriction sites, and directionally cloned into the pGEX-KG
expression plasmid. The pGEX-KG/Dnajc20 plasmid was transformed into calcium
competent BL21 E.coli cells for the production of GST (glutathione s-transferase)-
Dnajc20 fusion protein. The recombinant GST-Dnajc20 protein was purified by
incubation with glutathione beads. The Dnajc20 protein was purified from the beads by
incubation with thrombin, and the supernatant containing Dnajc20 was sent to
Diagnostics Scotland (Edinburgh, UK) for antibody production. Figure 4.3 shows the
detection ofmultiple bands using the antiserum on protein preparations from a wild-type
and a mutant mouse embryo subjected to SDS-PAGE and Western blotting (1 in 5000)
and a band corresponding to the predicted 17kDa Dnajc20 protein is readily identifiable
in the wild-type sample. However, this band is absent in protein from Dnajc20 mutant
embryos (Figure 4.3). Furthermore, protein from mutant embryos contains no band
corresponding to the 15kDa of the predicted mutant protein.
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Figure 4.3 Western blot analysis against Dnajc20
Figure 4.3 shows the result of a Western blot using rabbit antiserum
produced againstthefull length Dnajc20 protein following SDS-PAGE
of protein samples from wild-type and mutant Dnajc20embryos.
Multiple bands are detected, including a band of approximately 17kDa
that corresponds to the expected size of wild-type Dnajc20 protein
(arrow). This band is absentin the mutantprotein sample.
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The absence a band corresponding to the 15kDa mutant Dnajc20 protein suggests that
the mutant transcript is destroyed or, alternatively, the epitope recognised by the
antibody may correspond to the region encoded by exon 4 of the Dnajc20 transcript, and
therefore is not present in the mutant protein. Further analysis will be required to
determine whether the putative mutant protein is ever synthesised.
The rabbit antiserum is a useful tool for the further investigation of Dnajc20, with the
17kDa wild-type Dnajc20 protein being easily detected by SDS-PAGE and Western
blotting. However, the detection of additional proteins means that purification of
Dnajc20 antibodies from the antiserum will be required before other possible
applications are explored.
4.2.2 Homozygous Dnajc20 mutant embryos lack diphthamide
To determine whether eEF2 in the Dnajc20 homozygous mutant embryos had the
diphthamide modification, protein was prepared using modified RIPA buffer from each
embryo from an E10.5 litter (from an intercross from the CD1 background animals, see
Chapter 2). Fresh protein preparations were used as repeated freeze-thaw cycles have
been reported to cause the loss of diphthamide from wild-type samples, an event
confirmed by our own observations. The protein preparation was subjected to both
Native and SDS-PAGE and the eEF2 protein detected by Western blotting (Figure 4.4.A
and B). It has previously been shown that eEF2 with the diphthamide modification
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carries an additional positive charge compared to unmodified eEF2, causing it to migrate
more slowly by Native-PAGE (Figures 4.2 and 4.4.B)135. The genotype of each embryo
was confirmed by sequencing, using DNA prepared from the embryonic egg sac. The
protein from mutant embryos is in lanes 1, 3, 4, 5, and 9, lane 2, 7, and 8 are
heterozygous for the mutation in Dnajc20, and lane 6 is wild-type. eEF2 protein from
the Dnajc20 homozygous mutant embryos has migrated more quickly either than that of
the heterozygous or wild-type embryos, illustrating that the mutant embryos are
deficient in diphthamide biosynthesis. SDS-PAGE and Western analysis was also
performed against the Dnajc20 protein in the same preparations using the rabbit antisera
produced against the Dnajc20 protein (Figure 4.4.C). A band corresponding to the wild-
type 17 kDa Dnajc20 protein is present in the protein extracted from both wild-type and
heterozygous embryos but is absent in mutant embryos.
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Figure 4.4 Investigation of diphthamide biosynthesis
4.4.A Detection of eEF2 following SDS-PAGE. 4.3.B. Detection of eEF2 following
Native-PAGE. 4.4.C. Detection of Dnajc20 following SDS-PAGE. The same samples
were run in lanes 1 to 9 in the 3 experiments. Genotype Lane 1 Mutant (Mut), lane 2
Heterozygote (Het), lane 3 Mut, lane 4 Mut, lane 5 Mut, lane 6 wild-type, lane 7 Het,
lane 8 Het, and lane 9 Mut. In the mutant samples the eEF2 protein migrates faster
indicating diphthamide residue is not present (4.4.B). There is no difference in migration
by SDS-PAGE. No Dnajc20 protein (expected size 17kDa) is detected in the mutant
samples (4.4.Q.
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4.2.3 Cellular localisation of the Dnajc20 protein
It has previously been shown that the small zf-CSL protein from yeast
Ktil l/Dph3/YBL071w-a interacts with diphthamide biosynthesis factors as well as
translation proteins. The yeast orthologue Dnajc20, JJJ3/Dph4/YJR097w, was not
identified in the complex in this analysis. However, as this protein is required in the
same step of diphthamide biosynthesis as Ktil l/Dph3/YBL071w-a and they both have
the zf-CSL domain; I would predict that they have the ability to interact with the same
proteins, but not at the same time. To investigate the position of the mouse Dnajc20
protein in the diphthamide biosynthesis pathway, immunofluorescence experiments were
performed using an N-terminal FLAG-tagged Dnajc20 expression construct. To
investigate whether Dnajc20 co-localises with the diphthamide biosynthesis machinery
the FLAG-Dnajc20 construct was co-transfected into NIH-3T3 with a myc-tagged
Ovcal construct, the mouse orthologue of Dphl (a gift from Chun-Ming Chen) (Figure
4.5). Unexpectedly, the Dnajc20 and Ovcal tagged proteins did not co-localise. The
Ovcal protein localised to the perinuclear region of the cell, the same pattern that has
previously been published for this construct137, whereas the Dnajc20 tagged protein
displayed a cytoskeletal localisation. Co-staining of transfected cells for the Dnajc20
FLAG construct with phalloidin reveals that the Dnajc20 protein localises to the actin
cytoskeleton (Figure 4.6). The different localisation pattern of Dnajc20 and Ovcal
implies that the first step of diphthamide biosynthesis may require events in distinct
cellular compartments, and potential roles for Dnajc20 in this process will be discussed
93
Chapter 4 Dnaic20 is required for diphthamide biosynthesis
later in this chapter. However, this relies on the localisation of both the tagged Dnajc20
and Ovcal mirroring the in vivo situation. The Dnajc20 antibody detects Dnajc20 by
Western analysis, but reveals that it cross-reacts with other protein species. Purification
of this antibody may allow the in vivo localisation of Dnajc20 to be confirmed.
4.2.4 Initial investigation of Dnajc20 interactions
Co-immunoprecipitation (Co-IP) experiments have been performed in an attempt to
identify potential binding Dnajc20 and eEF2. Previous studies have identified a
cytoskeletal localisation of eEF2138"141, providing support for a possible interaction
between the two proteins. NIH-3T3 cells were transiently transfected with the FLAG-
Dnajc20 fusion protein and binding to endogenous eEF2 investigated by
immunoprecipitation (IP) with anti-FLAG antibody and detection of eEF2, or IP with
anti-eEF2 antibody and detection of FLAG, however, no interaction was identified. It is
possible that Dnajc20 interacts with unmodified eEF2 and is unable to bind eEF2 with
the post-translational diphthamide modification. This possible situation can be
investigated by either Co-IP using cells deficient in diphthamide biosynthesis or by the
production of a mutant eEF2 construct that is unable to be modified.
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Figure 4.5 Localisation of FLAG-Dnajc20 and Myc-Ovca1
4.5.A to C NIH-3T3 cells transfected with co-transfected with FLAG-Dnajc20 and Myc-
Ovcal. 4.4.A staining with anti-FLAG antibody. 4.5.B Staining with anti-Myc antibody.
4.5.C The FLAG-Dnajc20 and Myc-Ovca1 tagged proteins do not co-localise. The
FLAG-Dnajc20 protein localises to the cytoskeleton and the Myc-Ovca1 protein localises
to a region outside of the nucleus.
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Figure 4.6 FLAG-Dnajc20 localises to the cytoskeleton
4.6.A to F, staining of NIH-3T3 cells transfected with FLAG-Dnajc20, with anti-FLAG and
Phalloidin. 4.6.A and B staining with anti-FLAG. 4.6.C and D. staining with Phalloidin.
4.6.E and F merge. FLAG-DNAJ localises to the actin cytoskeleton.
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Co-IP experiments were also attempted to identify an interaction between the Dnajc20
and Ovcal fusion constructs. However, the Myc-Ovcal fusion protein was never
detected by IP. This raises the possibility that Myc-Ovcal is misfolded and is not a
functional fusion protein, a potential explanation for its different localisation to FLAG-
Dnajc20.
Further investigation of possible Dnajc20 interactions is still required. Even though no
interaction has been observed between Dnajc20 and either eEF2 or Ovcal, the reasons
stated above offer possible explanations for the failure to identify binding. Co-IPs with
the other members of the diphthamide biosynthesis pathway are also required to help
determine the role ofDnajc20 in this pathway.
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4.3 Discussion
Diphthamide, the cytosolic target of diphtheria toxin (DT) and Pseudomonas exotoxin A
(ETA), is a unique post-translational modification restricted to eEF2. The identification
that the yeast orthologue of Dnajc20, and both the mammalian and yeast small zf-CSL
protein, are required for diphthamide biosynthesis led to the investigation of whether the
same is true in mouse. The use of Native-PAGE revealed that eEF2 from Dnajc20
homozygous mutant mice migrated more quickly than eEF2 from wild-type or
heterozygous littermates, due to a charge difference between diphthamide and the
unmodified histidine residue. This illustrates that the Dnajc20 protein is required for the
first step of diphthamide biosynthesis in mouse.
The first step of diphthamide biosynthesis involves the transfer of a 3-amino-3-
carboxypropyl moiety from S-adenosylmethionine (AdoMet) to the C-2 imidazole of the
target histidine, and requires 4 proteins in yeast, Dphl to Dph4. The mechanism by
which these proteins catalyse this transfer is unknown. However, Dph3, the small zf-
CSL protein, has been shown to interact with Dphl, Dph2 and eEF2, as well as other
translation proteins136. Interactions between Dphl and Dph2 (and their orthologues)
have been shown in yeast and Drosophila in global yeast-two hybrid screens, and by co-
immunoprecipitation in yeast and mouse. The yeast Dph4 protein, the orthologue of
Dnajc20, has not been identified in these experiments.
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The zf-CSL domain is present in both Dph3 and Dph4 and their orthologues in the
higher eukaryotes. As the only conserved region present in the small zf-CSL proteins is
the zf-CSL domain itself, it is likely that the interactions with the other diphthamide
biosynthesis proteins and translation proteins would be mediated by this domain.
Therefore, it was hypothesised that the .(-domain zf-CSL proteins might be able to
interact with the same group of proteins as the small zf-CSL proteins, but at a different
time. To investigate this, initial experiments to show the localisation of the mouse
Dnajc20 protein were performed. Tagged Dnajc20 protein localised to the actin
cytoskeleton, whereas tagged Ovcal, the mouse orthologue of Dphl, displayed a
perinuclear localisation. The different localisation pattern of tagged Dnajc20 and Ovcal
implies that the first step of diphthamide biosynthesis may take place in two distinct
cellular compartments. If this was the case, an event requiring Ovcal/Dphl, and
presumably Dph2 and the small zf-CSL protein Dph3, would occur in the perinuclear
region, and a second event involving Dnajc20/Dph4 would take place at the
cytoskeleton. Alternatively, the Dnajc20 protein may not be directly involved in the 3-
amino-3-carboxypropyl transfer in the first step of diphthamide biosynthesis, and
instead, may provide a chaperone function in either the folding of one of the components
of the pathway or the formation of the required complexes.
Interestingly, the localisation of Dnajc20 with the actin cytoskeleton may suggest a
direct link to the eEF2 protein. A number of the translation elongation factors, including
eEF2138"141, eEFlalpha142 and eEFlbeta143, have been implicated as actin binding
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proteins and cross-communication between the protein synthetic machinery and the
cytoskeleton has been suggested. Initial attempts have been made to identify co-
localisation of Dnajc20 with eEF2, however, these have been unsuccessful, and further
analysis of the cellular compartmcntalisation of the eEF2 protein is required. Co-
immunoprecipitation experiments have also been performed in an attempt to identify
potential binding Dnajc20 and eEF2, but results to date suggest that there is no
interaction. The results of Native-PAGE suggest that almost the entire eEF2 protein
population has the diphthamide modification, and there is very little of the unmodified
precursor (Figure 4.3.B). As Dnajc20 is required for diphthamide biosynthesis, any
interaction with eEF2 may be restricted to the unmodified precursor. The same
experiment using cells that are deficient in diphthamide biosynthesis would allow the
further study of the potential interaction between Dnajc20 and unmodified eEF2, and the
function of Dnajc20 in the first step of diphthamide biosynthesis.
Localisation of the tagged Dnajc20 protein to the actin cytoskeleton suggests that the
role of Dnajc20 in diphthamide biosynthesis could be a result of association with eEF2.
There are a number of mechanisms that Dnajc20 could perform in this putative role,
based upon a requirement for a chaperone. It may be required for the folding of eEF2 in
to a structure that allows the first step of diphthamide biosynthesis to occur.
Alternatively, it might be involved in the correct localisation of eEF2, or other required
factors. Another possibility might be in the protection of the intermediate structure
produced in the first step of diphthamide biosynthesis. Results obtained in the same
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high-throughput yeast two-hybrid analysis that revealed an interaction between Dphl
and Dph2 provides another possibility in identifying the role of Dnajc20. In this screen
the yeast orthologue of Dnajc20, Dph4/JJJ3/YJR097w was found to physically interact
with an uncharacterised protein called YNL092w144. This protein is an outlier of the
AdoMet-dependent methyltransferase family, and it is tempting to speculate that this
enzyme might be involved in the 3-amino-3-carboxypropyl transfer from AdoMet to the
target histidine residue in the first step of the diphthamide biosynthesis pathway. The
orthologous protein in mouse, 2410127L17Rjk, shares 50% similarity, but is also
uncharacterised. However, this interaction may not represent the true physiological
situation, and further analysis is needed to firstly confirm any potential interaction, and
secondly, identify a requirement for this protein in diphthamide biosynthesis.
The presence of mouse models for diphthamide biosynthesis will provide valuable tools
for the study and eventual elucidation of its significance in normal cell physiology. The
Dnajc20 gene is the second diphthamide biosynthesis factor for which a mutation exists.
The mammalian orthologue of the Dphl gene is Ovcal, a ubiquitously expressed gene
first identified as a potential tumour suppressor in humans145. The total or partial loss of
Ovcal expression has been observed in ovarian tumour tissues and cell lines145'146. Due
to this association with ovarian cancer, a knockout Ovcal mouse has previously been
26
generated" . The homozygous phenotype of the Ovcal null mouse is very similar to
ENU generated Dnajc20 mutant animals.
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Ovcal null mice on a B6/129 background die soon after birth with a body weight around
50% of their wild-type and heterozygous littermates26. Furthermore, a proportion of
Ovcal null embryos die around midgestation, a situation similar to that with the
Dnajc20 homozygous mutant embryos. The severity of the Ovcal null phenotype is
also background dependent; on a 129/SvEv genetic background all embryos die by
El 3.5. Ovcal null embryos display developmental delay of up to 24 hours compared to
wild-type and heterozygous littermates. Figure 4.7.A and B illustrate the E9.5 and
El 1.5 Ovcal null embryonic phenotype and Figure 4.7.C shows the Dnajc20 null
embryos. The most striking phenotypic similarity between the Dnajc20 mutant embryos
and the Ovcal null animals is preaxial Polydactyly of the hind limbs (Figure 4.7.D to F).
There are phenotypic differences between the Dnajc20 and Ovcal homozygous mutants.
All of the Ovcal null mice that were born had cleft palates, an abnormality not observed
in the Dnajc20 mutant animals. However, differences such as this could be due to the
genetic backgrounds. There are additional features that have been observed in the
Ovcal mutants, including focal liver damage in around half of null embryos and an
immature lung phenotype, which need to be investigated in the Dnajc20 homozygotes.
102
Chapter 4 Dnaic20 is required for diphthamide biosynthesis
nnn
Figure 4.7 Dnajc20 mutant embryos are similar to Ovcal mutant embros
Figure 4.7.A,B,D and E are from Chen and Behringer, Genes & Development. (2004)26
4.7.A. E10.5 Wild-type embryo, E11.5 wild-type embryo, and two E11.5 Ovcal mutant embryos
4.7.B. E9.5 Wild-type embryo, and two E11.5 Ovcal mutant embryos. 4.7.C. Wild-type C10.5
embryo, and two Dnajc20 mutant embryos. 4.7.D Hindlimb of wild-type E14.5 embryo. 4.7.E.
Hindlimb of Ovcal mutant embryo with preaxial Polydactyly (red arrow). 4.7.F. Hindlimb of
Dnajc20 mutant embryo with preaxial Polydactyly (white arrow).
103
Chapter 4 Dnaic20 is required for diphthamide biosynthesis
The cellular phenotype of Ovcal mutant mouse embryonic fibroblasts (MEFs) has been
investigated and a defect in proliferation identified26. The Ovcal null MEFs have a
reduced S-phase population compared to OVCA1 heterozygous MEFs. Analysis of the
retinoblastoma (Rb) gene revealed a reduced phosphorylation state in the Ovcal null
MEFs. Phosphorylation of Rb in late G1 promotes entry into S-phase by releasing the
E2F transcription factors, whereas dephosphorylation of Rb results in it binding to E2F
transcription factors and repressing their transcriptional activity147. The phosphorylation
of Rb is consistent with a proliferation defect in the Ovcal mutant MEFs . The
proliferation defect observed in the OVCA1 deficient MEFs suggests that OVCA1 is a
positive regulator of cell proliferation, or alternatively, the loss of OVCA1 results in the
activation of a cell cycle checkpoint. The OVCA1 gene is present on the short arm of
human chromosome 17 close to the cell cycle regulator p53, and deletion of both genes
is observed in human tumours26. To whether the loss of p53 could rescue the
proliferation defect observed in the OVCA1 mutant MEFs Chen and Behringer generated
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MEFs deficient for both genes . The close proximity of the two genes required a
fortuitous spontaneous recombination event to produce mice with mutations in both
OVCA1 and p53. Double mutant MEFs produced from these animals had normal
proliferation in comparison to the Ovcal null MEFs. In embryos with homozygous
mutation of both OVCA1 and p53 some of the developmental abnormalities seen in the
OVCA1 null embryos, including size and the cleft palate phenotype, were partially
improved but the embryonic lethality remained. These results do suggest an interaction
between OVCA1 and p53 in at least a subset of cell types, probably through the
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induction of a p53 cell-cycle checkpoint, however, a p53 controlled checkpoint alone
does not completely explain the homozygous Ovcal phenotype26.
Due to the loss of OVCA1 expression in human ovarian tissue and ovarian cancer cell
lines and the loss of both OVCA1 and p53 in some tumours, Chen and Behringer
investigated tumourigenesis in a variety of Ovcal/p53 genotypes over a two year
26
period' . 50% of the Ovcal heterozygous animals tested had developed tumours by two
years of age, suggesting that OVCA1 acts as a tumour suppressor. The tumour spectrum
included epithelial tumours of the lung and liver as well as lymphoid and stromal
derived malignancies, suggesting a global tumour suppressor role2 '148. However, only
one ovarian tumour was identified in the mutant Ovcal heterozygotes. The heterozygous
loss of Ovcal also increased the tumour latency and load ofp53 mutant mice, implying
a joint role for Ovcal and p53 in some cancer types148. It is unclear whether the
tumourigenesis in Ovcal heterozygous animals requires the loss of heterozygosity, or if
haploinsufficiency of OVCA1 along with additional factors such as mutation of other
tumour suppressors is sufficient for a tumour to develop148. The presence of an Ovcal
conditional mutation will provide further information about its role in tumourigenesis.
It will be interesting to see if Dnajc20 heterozygotes are predisposed to develop
Dnajc20 mutant mice, together, with the Ovcal mutant, will provide significant
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information in the further investigation of the requirement of diphthamide in translation,
mammalian development, checkpoint control and tumourigenesis.
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5.1 Introduction
5.1.1 WAGR Syndrome
The region ofmouse chromosome 2 deleted in the Pax6Sey~IH mice is syntenic to human
chromosome 1 lp 13. Deletion of either part or all of human chromosome 11 p 13 results
in the phenotypically variable WAGR syndrome (Wilms tumour, aniridia, genitourinary
abnormalities and mental retardation), which was identified as a syndrome in the mid
1960s with the recognition that patients with aniridia were of a much higher risk of the
childhood kidney cancer Wilm's tumour149. Analysis of the WAGR deletion
subsequently led to the identification of Wilms tumour gene WTJ'50, which is also
responsible for the genitourinary abnormalities, and PAX6 which is mutated in
aniridia151. The gene, or genes, responsible for the mental retardation component of
WAGR syndrome are yet to be identified.
Wilms tumour is an embryonal neoplasm of the kidney that occurs at a rate of 1 in
10,000 children usually between the ages of 2 and 4 years, however in children with
1 S?
aniridia the occurrence is 1 in 3 . Mutations in the WT1 gene are responsible for
between 10 and 15% ofWilms tumours.
Aniridia is an autosomal dominant disorder of the eye which shows almost complete
penetrance, although the severity of the disorder varies in its presentation even among
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patients with the same mutation, and is characterised by the complete or partial absence
of the iris, and is associated with cataract and glaucoma. Aniridia occurs at a rate of
approximately lin 50,000 to 100,000, with around two thirds of the cases being familial,
only a small proportion of cases are associated with WAGR syndrome. The
heterozygous loss ofPAX6 has been shown to be responsible for the majority of aniridia
cases, due primarily to nonsense mutations151'15 .
The cause of the mental retardation phenotype, which is a characteristic of many
contiguous gene deletion syndromes, has yet to be determined, although the gene, or
genes, responsible are thought to map distally to WT1 and PAX6xsa. The desire to
identify the cause of the mental retardation has resulted in an increased effort to isolate
and characterise the genes within the WAGR deletion region, with the aim of achieving
a better understanding of the genes involved in the development and function of the
u ■ 48,154bram
In addition to the defining abnormalities of WAGR syndrome other features have also
been reported. A small number of WAGR patients have been described with morbid
obesity, leading to the proposal of the WAGRO acronym and the suggestion that there is
an obesity gene present in the 11 p 13 region. Other characteristics associated with
WAGR syndrome include a small head circumference, thought to be due to the loss of
PAX6, as well as a low birth weight and body size.
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Recently four WAGR patients have been reported with bilateral hallucal
20 21
Polydactyly ' . These reports, along with Malpeuch et al 's identification of a WAGR
patient described as having "hexadactyly and syndactyly of the first and second toes"
suggest the presence of a Polydactyly gene associated with WAGR syndrome155. There
is remarkable similarity between the Polydactyly WAGR patients and the Polydactyly of
the Dnajc20 mutant mice. The appearance of the Polydactyly in the Dnajc20 and Ovcal
mutant mice and the relative rarity of this type of preaxial Polydactyly (OMIM: 174400)
strongly implies that the loss of DNAJC20 is the cause of Polydactyly in WAGR
syndrome.
5.1.2 The human Dnajc20 gene in WAGR syndrome
The WT1 and PAX6 genes are 700kb apart on human chromosome llpl3, the human
orthologue of DNAJC20 is present a further 400kb telomeric of PAX6 (Figure 5.1), and
would be expected to be heterozygously lost in a large proportion ofWAGR patients.
Chromosomal aberrations have been mapped in many WAGR individuals, for instance
Crolla et al (1997)156 and Crolla and van Heyningen (2002)l57, reported 12 WAGR
patients, with variable manifestations of the WAGR clinical features. Of these 5 have
lost DNAJC20 based on the heterozygous loss of the cosmid A4160, which contains the
marker D11S9J4 (Figure 5.1). In the remaining WAGR patients the cytogenetics was
not reported. The mapping information from WAGR and aniridia patients such as these
suggests that loss of one copy of DNAJC20 in humans does not generally contribute to
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Figure 5.1 Gene order on human chromosome 11
The position of DNAJC20 in relation to PAX6 and WT1 andthe D11S914
marker on h u man ch romosome 11.
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the typical manifestation of the syndrome. However, the recent reports of WAGR
syndrome patients with Polydactyly suggest that there is a gene responsible for
Polydactyly located contiguously to the WAGR region, and our mouse data makes
DNAJC20 gene the leading candidate.
Individuals have been described with deletions very similar to those in these WAGR
with Polydactyly patients, as well as deletions that extend further both proximally and
distally in WAGR patients with no Polydactyly reported. If there is a gene in the
WAGR region responsible for hallucal Polydactyly the loss of one copy is not generally
sufficient to result in the Polydactyly phenotype, and like the recessive Dnajc20
mutation in the mouse, would most likely need to be homozygous. Therefore a second
hit in the remaining copy of the gene would be required.
5.2 Results
Manoukian et al reported the case of a 30 month old baby girl with bilateral preaxial
Polydactyly of the feet in addition to the typical clinical features ofWAGR syndrome20.
They identified a deletion, del(lI)(pl3pl4.1), which is between 6.1 and 21.7Mb in
length. The human orthologue ofDnajc20 is lost in the minimal deletion interval.
Bremond-Gignac et al reported three patients with hallucal Polydactyly of the feet, in
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addition to WAGR syndrome (Figure 5.1.B). The patients included a pair of
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monozygotic twins with bilateral hallucal Polydactyly and a third unrelated patient with
hallucal Polydactyly of the right foot.
Molecular cytogenetic studies of one of the MZ twins (presumed to be representative of
both twins) showed a deletion with break points on the boundary of band lip 12 and
11 p 13 extending to proximal 1 lpl4, with an estimated size between 2.5Mb and 7.0Mb.
The absence of the marker D11S914 shows that human DNAJC20 is deleted in these
patients. Analysis of the third patient revealed a larger deletion del(l 1 )(p 13p 15.1).
Due to the similarity between the Polydactyly in these patients (shown in Figure 5.2) and
that observed in the Dnajc20 homozygous mice it was decided to sequence the second
allele of the human DNAJC20 in order to identify a potential second mutation in the
20
gene. DNA was provided by Radice and Perotti" from their patient as well as both of
the probands parents. They had previously shown that the deletion carrying
chromosome was of paternal origin; therefore a second genetic event within Dnajc20
21would be maternal. Bremond-Gignac provided DNA from the MZ twins, however,
they were unable to supply a DNA sample from the third patient.
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Figure 5.2 WAGR syndrome with Polydactyly
20
Figure 5.2.A. From Manoukian et al, American Journal of Medical Genetics (2005).
X-ray showing bilateral hallucal Polydactyly of a WAGR syndrome patient. 2,
Figure 5.2.B. From Bremond-Gignac et al, American Journal of Medical Genetics (2005).
X-ray showing bilateral hallucal Polydactyly of a WAGR syndrome patient, the image is rep¬
resentative of both monoztgotic twins.
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Primers were designed to sequence across the exons and splice sites of the human
DNAJC20 gene based on the ensembl annotation. The current ensembl annotation
suggests that the gene is encoded by 6 exons, compared to the 5 mouse exons. However
the 444bp fifth intron of human DNAJC20 444 bp present in the 3 prime UTR contains
non-consensus 5 prime and 3 prime splice-sites and was treated as a mis-annotation and
was sequenced as being part of the true fifth exon. Additionally, exon 1 which is 456bp
in mouse is annotated as being only 26bp in humans, therefore primers were designed so
that a homologous sequence to the mouse Dnajc20 exon 1 was amplified.
PCR and sequencing were performed on the DNA samples of the three WAGR patients
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with Polydactyly, as well as the parents of the proband reported by Manoukian et al .
No base changes were identified in any of the samples, showing that the hallucal
Polydactyly is not a result of a second coding or splice mutation in human DNAJC20.
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5.3 Discussion
The recent reports of WAGR patients with preaxial Polydactyly of the feet along with
one previous description suggests that Polydactyly is a component ofWAGR syndrome,
although only in a small number of cases. The similarity of the Polydactyly in these
patients to that in the Dnajc20 mutant mice is striking, and the human DNAJC20 gene is
an obvious candidate for this additional abnormality of WAGR syndrome. The small
number of WAGR syndrome patients with Polydactyly, and the loss of the DNAJC20
gene in WAGR patients without Polydactyly, suggested that the manifestation of the
abnormality could be due to a second genetic event. However, after sequencing the
coding exons, splice sites and 5' and 3' UTRs I have been unable to identify a second
allele within the DNAJC20 gene of these WAGR patients.
The DNAJC20 gene is still a candidate for the occurrence of hallucal Polydactyly with
WAGR syndrome. The similarity between the two phenotypes, preaxial Polydactyly
with duplication of the first digit rather than the more common duplication of the other
digits supports this conclusion.
Although no coding change was identified, there is still the potential of a second genetic
event. There is a possibility that the Polydactyly is caused by a non-coding mutation
within the transcript or promoter region of the remaining copy of the DNAJC20 gene,
116
Chapter 5 Analysis of a potential homologous mutation in humans
however the absence of further tissue from the probands makes the investigation of
expression and localisation of the transcript unachievable.
Another explanation, and perhaps the most likely, is that the Polydactyly is a low
penetrant trait of WAGR syndrome due to haploinsufficiency of DNAJC20 in some
individuals.
The identification of preaxial Polydactyly of either one or both feet in 5 individuals with
WAGR syndrome suggests that it is a true clinical manifestation of the disorder, albeit
only in a small number of cases. The DNAJC20 gene is the leading candidate for this
disorder, with the likely cause either being haploinsufficiency or via a second genetic








ENU mutagenesis of the mouse provides a method for the identification of novel
phenotypes with the advantage that no assumptions are needed about the factors
involved, and thus supplies an effective means to identify novel genes and pathways.
Region-based screens are a time and cost effective approach in the identification of
recessive mutations, especially in the identification of the mutated loci, as the mutation
is immediately localised to a specific chromosomal location, sidestepping the need to
map the mutation. Our group has recently performed a region-based ENU mutagenesis
screen utilising the Pax6SeyIH deletion, which removes a 3Mb region of mouse
chromosome 2, and includes the Pax6 and Wtl genes47. This region is of interest for
several reasons including; firstly the presence of developmentally relevant factors, which
are not explained by known genes within the region, and secondly, relevance to human
disease, with deletion of the syntenic region in humans causing the phenotypically
variable WAGR syndrome.
At the outset of this project a single mutation had been recovered which is lethal against
the Pax6Sey~w deletion. Intercrosses of carrier animals revealed that the mutation was
predominantly lethal when homozygous, however, some homozygotes did survive and
these were small with preaxial Polydactyly of their hind limbs. The study detailed
within this thesis details the further characterisation of the mutant phenotype and, by
sequencing exons within the candidate region, the identification of splice mutation in a
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functionally novel J-protein. The mutation, a T to A transversion at position +2 of the
splice donor site in intron 4, results in the in-frame skipping of the adjacent exon 4 from
the mRNA transcript. However, current evidence suggests that either no protein is
made, or that the mutant protein is degraded. A bioinformatic approach has been used to
clarify the mouse J-protein family in mouse, and led us to suggest the name Dnajc20 for
this gene, in line with the current nomenclature. Bioinformatic characterisation of the
Dnajc20 protein identified orthologues throughout eukaryotic evolution, as well as the
identification of the C-terminal zf-CSL domain, and its presence in the small zf-CSL
proteins, which are also present as one copy in all eukaryotes.
Recent work by Liu et al has identified a role for the zf-CSL proteins in the synthesis of
diphthamide, the cytosolic target of the bacterial toxins DT and ETA, in yeast and CI10
9^95 1^5
cells " ' . Consequently, investigation of the Dnajc20 homozygous mutant mice
revealed that they were deficient in diphthamide biosynthesis. Ovcal, another
diphthamide biosynthesis factor has been mutated in the mouse26 and shows a very
similar homozygous phenotype to the Dnajc20 mutant mice. The identification of the
9 "5
diphthamide biosynthesis proteins , together with the animal models provided by the
Ovcal26, and Dnajc20 mutations provide a major breakthrough in the study of




6.2 Diphthamide biosynthesis and its biological relevance
The diphthamide modification was first identified as the target for DT and ETA 25 years
ago , however, its significance in normal cell physiology is yet to be determined.
Mutation of the histidine 699 residue of yeast has implied a structural role for
diphthamide either in eEF2 or within the ribosome. Substituting the histidine residue for
each of the other 19 amino acids results either non-functional eEF2, illustrating the need
for diphthamide in normal translation, or temperature-sensitivity156, and has led to the
suggestion that diphthamide may be responsible for the overall structure and stability of
eEF2 23.
An alternative function of diphthamide is as a site of regulation of protein synthesis.
Indeed, there have been previous reports of an endogenous factor that can ADP-
ribosylate eEF2, and unlike DT and ETA ADP-ribosylation, would presumably be
reversible1 '' 3. However, this putative ADP-ribosyltransferase has yet to be identified.
There have also been reports suggesting the presence of a cytoplasmic factor that
inhibits both DT and endogenous ADP-ribosylation of diphthamide163'164. Interestingly,
the most recent of these reports propose that the inhibitor is actin164, which, along with
the localisation of Dnajc20 (Chapter 4), provides an additional link between eEF2,
diphthamide and the cytoskeleton.
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The best evidence for the function of diphthamide comes from recently published work,
which has shown that ETA toxin achieves its recognition of eEF2 by mimicry of
ribosome structure159. Jorgensen et al have determined four crystal structures of
complexes of yeast eEF2 and the catalytic subunit of ETA toxin159. By superimposing
this structure onto the previously identified cryo-electron microscope reconstruction of
eEF2 in complex with the SOS ribosome160 they revealed a remarkable similarity
between the orientation of ETA and the region of the ribosome that interacts with
eEF2159. ETA, and presumably DT, by mimicking this ribosomal structure reduce the
possibility that a host organism can evolve toxin resistance as coordinated mutations in
both the ribosome and eEF2159. Interestingly, a possible interaction between
diphthamide and two universally conserved adenine residues that are essential for tRNA
recognition at the A-site in the small ribosomal subunit was also identified159. These
two adenines undergo a conformational change, switching from a stacked (closed)
position in the absence of tRNA to a flipped out (open) position in the presence of
cognate tRNA159. Jorgensen et al propose that diphthamide may be required for the
stabilisation of the stacked position of the adenines, and therefore be essential for
maintaining the correct reading frame during translocation across the ribosome159. The
recent identification of the majority of the proteins required for diphthamide
23
biosynthesis provides a starting point for the further study of diphthamide . An
immediate consequence of identifying the diphthamide biosynthesis proteins in yeast
and CHO cells has been to assign a biological role for the Dnajc20 and Ovcal proteins,
providing two mouse models for investigation of the physiological relevance of
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diphthamide (see chapter 4). The lack of obvious phenotypes in both yeast and CHO
cells deficient in the synthesis of diphthamide has made the functional relevance of
diphthamide difficult to study125"127. Already, with the animal models, it can be
concluded that the presence of diphthamide is required for normal physiological
development and postnatal survival. The spontaneous generation of tumours in the
Ovcal heterozygous mice also raises the possibility that diphthamide is linked to cell-
cycle checkpoint control and tumourigenesis. If diphthamide is required for the
maintenance of the correct reading frame during translation, it might be expected that
mutations in the diphthamide biosynthesis pathway result in the synthesis and possible
accumulation of mutant proteins, a situation that would be expected to induce
checkpoint control.
The mutations in Dnajc20 and Ovcal, as stated previously, supply animal models for the
further study of the functional relevance of diphthamide in normal cell physiology.
However, how the Dnajc20 (Dph4), Ovcal (Dphl), Dph212 (Dph2), and Zcsl2 (Dph3)
proteins function in the first step of diphthamide biosynthesis is still unknown, and a
complete knowledge of their role in this synthetic process is required to properly
understand the diphthamide modification. Binding studies have previously shown that
yeast Dph3 is able to associate with Dph l and Dph2136. It has been suggested that these
three proteins work as a multiprotein complex to catalyse the transfer of 3-amino-3-
9 7
carboxypropyl on to the target histidine of eEF2 . The presence of a homologue of the
Dphl and Dph2 proteins in archaebacteria supports this hypothesis. If diphthamidc
123
Chapter 6 Discussion
biosynthesis occurs in the same way in both eukaryotes and archaebacteria it is likely
that the Dphl, Dph2 and their archaebacterial homologue provide the catalytic domain
required for the first step of the modification. The presence of the zf-CSL domain in
Dnajc20/Dph4 and Zcsl2/Dph3 implies that these proteins share a common substrate.
The localisation of Dnajc20 (described in chapter 4) and the proteins that have been
identified as interacting with yeast Dph3136 suggest eEF2 as a likely candidate. As
described previously, the use of diphthamide deficient mouse embryonic fibroblasts
provides a suitable platform for the study of the putative association between eEF2 and
Dnajc20.
Another issue concerning the role of Dnajc20 in the synthesis of diphthamide is its
function as an Hsp70 co-chaperone. A starting point for the identification of the
requirement of chaperone function in the first step of diphthamide biosynthesis will be
the identification of the in vivo Hsp70 chaperone partner of Dnajc20. The Dnajc20
protein has previously been shown to activate the ATPase activity of mouse Hsp70
proteins BiP and Hsc7022. Of these, the constitutively expressed Hsc70 is a good
candidate for an in vivo partner of Dnajc20 as it has previously been implicated in the
organisation of the actin-cytoskeleton165. Therefore, to properly characterise the role of
Dnajc20 in the first step of diphthamide biosynthesis it will be necessary to identify both
its substrate(s) and Hsp70 chaperone partner.
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6.3 Dnajc20; a model for type III J-protein evolution
The only region of conservation between the type III subclass of J-proteins and the other
family members ofmolecular chaperones is the J-domain (see chapter 2). Many of these
type III J-proteins, along with the J-domain, have specific substrate binding domains that
define their function. The structural arrangement and specific functions of these type III
J-proteins brought about the hypothesis that J-domains have been co-opted by some
proteins through evolution in order to recruit chaperone power to a novel function54.
The presence of both an orthologue of Dnajc20 and the small zf-CSL protein in the same
biological process throughout eukaryotes promote Dnajc20 as a model for the hypothesis
of type III J-protein evolution. Structurally it has an N-terminal J-domain and a C-
terminal zf-CSL domain. The theory of J-protein evolution suggests an ancient zf-CSL
protein will have inherited a J-domain by some genetic event. This new J-domain zf-
CSL protein will have recruited chaperone power to a specific process. The
identification of a role for both the small zf-CSL protein and the Dnaj20 protein in
diphthamide biosynthesis supports this premise. A probable starting point would have
been a single gene encoding an ancestral small zf-CSL protein. This gene, via a process
of duplication and recombination will have come in to the vicinity of a locus encoding a
J-domain, resulting in the presence of both a small zf-CSL and J-domain zf-CSL
encoding genes early in eukaryotic evolution. The recruitment of a J-domain to
diphthamide biosynthesis, and therefore an Hsp70 protein and chaperone power, will
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presumably have improved functional efficiency in the first step of the modification.
The maintenance of both proteins in all eukaryotes examined suggests the early
evolution and preservation of essential roles for both proteins in diphthamide
biosynthesis.
6.4 Is Dnajc20 required for other cellular processes?
The identified role for Dnajc20 in diphthamide biosynthesis is, as discussed, defined by
the presence of the zf-CSL domain. However, as described in Chapter 3, this domain is
also involved in other biological processes via the small zf-CSL proteins (Chapter 3).
This raises the question as to whether Dnajc20 is restricted to the diphthamide
biosynthesis pathway, or if it shares more functions with the small zf-CSL proteins in
transcription and/or exocytosis via an association with the Elongator complex.
The yeast small zf-CSL protein was originally identified as Ktill, one of the factors
resistant to Kluveromyces lactis zymocin106. The subunits of the Elongator complex
have been isolated as the TOT (target of toxin) mutants, which are phenotypically the
same as the Ktil 1 mutation. The yeast Dphl and Dph2 mutants have also been shown to
be moderately resistant to zymocin, suggesting there may be cross-talk between the
diphthamide biosynthesis and zymocin resistance pathways • However, mutations in
the Elongator complex subunits are not resistant to DT136. Therefore, a link between
diphthamide biosynthesis and zymocin resistance is not bi-directional. Furthermore, the
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zymocin resistance phenotype of Dphl and Dph2 mutant yeast strains could be due to
interference with the function of the wild-type Ktill/Dph3 protein. Yeast lacking
Dph4/JJJ3/YJR097w have not been tested for zymocin resistance, an experiment that
could exclude the possibility of a link to Elongator function.
The Elongator complex is conserved from yeast to humans, and some of the human
subunits can substitute for their yeast counterparts, suggesting functional equivalence.
However, the role of Elongator complex in the cell is ambiguous, a characteristic that
may prove problematic in the investigation of an association between Dnajc20 and
Elongator. As discussed earlier, it was originally assigned a role in RNA polymerase II
transcriptional elongation via its histone acetylation capacity110'112'166. However, whether
this is the case has been called into question, for example, there are multiple reports
suggesting that Elongator does not enter the nucleus. The alternative role for Elongator
in polarised cell-surface transport has been identified more recently"9, and is related to
the identification of the human small zf-CSL protein as DelGIPl, downregulation of
which, leads to increased proteoglycan secretion120.
The production ofmouse embryonic fibroblasts, homozygous for the Dnajc20 mutation,
will allow initial experiments in the investigation of any potential role associated with
Elongator function. For instance, the yeast Ktil 1 protein has been shown to protect Elp 1
from cleavage136'167, a process that can be easily examined in Dnajc20 mutant cells. The
identification of an association between Dnajc20 and Elongator is therefore achievable,
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however, the functional relevance will not be known until the role of Elongator has been
elucidated.
6.5 Human DNAJC20
One of the aims of ENU mutagenesis of the mouse is the production of animal models
for the study of human disease pathogenesis. Indeed, as stated previously, the ENU
mutagenesis screen recently performed by our group against the region of mouse
chromosome 2 around the Pax6 gene has relevance to human disease in the form of
WAGR syndrome. The human DNAJC20 gene is within 400kb ofPax6, and one copy is
regularly lost in WAGR patients. As discussed in Chapter 5, the similarity between the
preaxial Polydactyly of the mutant mouse and that recently reported in four WAGR
20 21
patients makes DNAJC20 the leading candidate for this abnormality ' . However,
sequencing of the remaining copy of the human DNAJC20 mutations did not reveal any
additional mutations. Therefore, if human DNAJC20 is the cause ofPolydactyly in these
patients it is most likely as a low penetrant trait due to haploinsufficiency. If DNAJC20
is pathogenic due to hemizygosity, it raises the possibility that it is responsible for other
abnormalities in WAGR patients. Another similarity between WAGR patients and the
Dnajc20 homozygous mutant mice is the growth abnormality. Many WAGR patients
have a low birth weight and body size. The loss of one copy of DNAJC20 is a possible
contributor to the small size ofWAGR patients, however, it is probably a result of the
loss ofmultiple genes within the region.
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The potentially most relevant consequence of mutations in human DNAJC20 is not yet
known. As mentioned previously, the phenotype of the Ovcal mice links diphthamide
to tumourigenesis, and further study of the Dnajc20 mutant mouse is required for a full




It has been 25 years since the cytosolic target of the ADP-ribosylating diphtheria toxin
and Pseudomonas exotoxin A was identified as diphthamide, a post-translational
modification unique to eEF2. However, the function of diphthamide in normal cellular
physiology has so far evaded characterisation. Over the past two years there has been a
significant breakthrough in the study of diphthamide biosynthesis; first with the
identification of the proteins required in its synthesis, and second, the Ovcal mutant
mouse. The work described in this thesis further contributes to this field of study,
showing for the first time the requirement for Dnajc20/Dph4 in diphthamide
biosynthesis in a higher eukaryote, and confirming the requirement of diphthamide for
normal physiological development and postnatal survival. The Dnajc20 mutant mouse
supplies an additional model for the investigation of diphthamide and its relevance to





Chapter 7 Materials and Methods
7.1 Nucleic acid manipulation
All reagents were analytical grade and supplied by Sigma, Invitrogen, BDH, Roche,
Qiagen and Fisher. All nucleic acid manipulation was performed in 1.5ml centrifuge
tubes. General lab solutions are prepared by HGU technical service staff, autoclaved,
and stored at room temperature unless otherwise stated.
7.1.1 Solutions
EDTA
EDTA (ethyldiaminetetra-acetic acid di-sodium salt) was dissolved in dFEO, and
adjusted to pH 8.0 by adding 5M NaOH.
SDS
SDS (Sodium dodecyl sulfate) crystals are dissolved in dFEO at 68°C. The solution is
adjusted to pH 7.2 by addition of concentrated HC1.
NaCl
NaCl (Sodium Chloride) is diluted in dEEO.
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Tris.HCl
Tris base (tris[hydroxymethyl]aminomethane) was dissolved in dH20, and the desired
pH achieved by addition of concentrated HC1.
TE buffer
lOmM Tris.HCl (pH 7.5), ImM EDTA.
Quick lysis buffer. IX









dH20 added to a final volume of 1 litre. 20X stock solution was diluted to IX working
solution with ddH2Q.
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Gel loading buffer, IPX
Reagents are diluted in dH20 to give a final concentration of 40% Sucrose, lOOmM
EDTA, and 1% OrangeG.
PCR Primers
Primers were purchased as lyophilised, desalted compounds (MWG Biotech and
Invitrogen). Stocks were made up to lmg/ml with ddll20 and stored at -20°C. Working
stocks were diluted to lOOng/pl with dH20 and stored at -20°C.
dNTPs
dNTPs were purchased as individual lOOmM stocks (Abgene). Working stocks of
lOmM were made by mixing lOpl of each dNTP (dATP, dCTP, dGTP, dTTP) with 60pl
of dH20, and stored at -20°C.
7.1.2 Preparation of DNA
Tissue samples, ear clips or egg sacs, are suspended in 0.5ml Quick Lysis buffer and
2.5pl of 25mg/ml Proteinase K, mixed and incubated overnight at 50°C. The samples
are vortexed for 15 seconds followed by centrifugation at 13,000 rpm for 5 minutes. The
supernatant is transferred to a fresh 1.5 ml eppendorf, and 0.5ml of isopropanol is added.
The samples are mixed and DNA precipitate for 10 minutes at room temperature. The
samples are centrifuged at 13,000 rpm for 10 minutes. The supernatant is discarded and
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pellet washed with 70% ethanol. The supernatant is removed and the pellet allowed to
dry at room temperature. The pellet is then resuspended in 50pi TE buffer or dFFO.
7.1.3 Preparation of RNA
Total RNA was isolated from embryos using the RNAgents Total RNA Isolation
System (Promega) following the manufacturers instructions. Tissues are homogenised
in denaturing solution (Promega). 2M Sodium acetate (pH 4.0) is added to the tissue
homegenate, mixed thoroughly, and incubated on ice for 20 minutes. Following
incubation, an equal volume of Phenol:ChloroformTsoamyl alcohol is added to the
samples. The samples are then incubated on ice for 20 minutes. The samples are mixed
by inversion and centrifuged at 13,000 rpm for 20 minutes at 4°C. The aqueous phase ,
which contains the RNA, is transferred to a fresh eppendorf. An equal volume of
isopropanol is added and samples stored at -20°C overnight. The samples are
centrifuged for 30 minutes at 4°C. The supernatant is then removed and the pellet
washed with 80% ethanol. The RNA is then dried and re-suspended in nuclease free
dITO. RNA samples are stored at -70°C.
7.1.4 Determination of DNA and RNA concentration
In order to accurately calculate the concentration of DNA or RNA present in a sample,
absorbance in a spectrophotometer at 260nm (A26o) was determined. The
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spectrophotometer was calibrated using a blank sample containing H20. Samples were
diluted in DEPC treated water, and the absorbance at 260nm was measured. These
measures correspond to the following concentrations; 1 A26o unit of dsDNA = 50pg/ml
H20 and 1 A26o unit of ssRNA = 40pg/ml H20. Concentration (pg/ml)= A26o value x
dilution factor x 50pg/ml (DNA)/ 40pg/ml (RNA).
7.1.5 Polymerase Chain Reaction (PCR)
PCR reactions using BIO-X-ACT™ polymerase, lOx OptiBuffer and MgCl2 (Bioline)
were carried out to amplify specific regions of genomic DNA in the search for the
MUTS1/14 mutation and the sequencing of human Dnajc20 (See Table 7.1). After




Forward primer (lOOng/pl) 0.6pl
Reverse primer (lOOng/pl) 0.6pl
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Table 7.1 PCR primers used to sequence genes
Exon Forward Primer 5' to 3' Reverse Primer 5' to 3'
Dnajc20exon 1 TCCTCATCCTTATCACCAACTG CTCCTGTTTGATGAAGGAGTGG
Dnajc20 exon 2 CTTAAATTTCTGGTCGCACTGA TACATGGCATTTATGGGACATT
Dnajc20 exon 3 AAACAGTGGCAATAACTGGATG TCACCACCCTTACTTTTGATTG
Dnajc20 exon 4 GACCCAGAAAGAGGAAAACATT ATGGCTGCACAAGAGATACATT
Dna]c20 exon 5 TGACGCTGTGTGGAGCCAGGGG AGCTCTGATGGAGGAGCTCCAC
Wt1 exon 1 TTACTTACCTAGACGGCCTTGC CTCCTGTTTGATGAAGGAGTGG
Wt1 exon 2 ACGACTCTACTGCTGACGAGAG AAATGTTTCTACTCGCTCTCCC
Wt1 exon 3 GTCTGATGCTCAGCAAGCTCT GGATTTCCAGGATCTAGTCTCG
Wt1 exon 4 TCATTATTTTAGAAGGCATGTGCT TTTTCTAAGCCTAGGCCTGTTC
Wt1 exon 5 TCTTGACGTGGTCATTAGCTTT GAAGAAGGCAGAGGTAGTACG
Wt1 exon 6 AGTTTTGGATTCTGGCTCCTAT TTGAATACCTCTTGGTTTGCTG
Wt1 exon 7 AGGGTATGGAAGCAAACTTTTT ACAACCTTTCTACCCCACAAGT
Wt1 exon 8 AGTACTACCCTAACAGGCTCCC AAAGAAAAGTCTCCAGGTGAG
Wt1 exon 9 AATCAAAGAAATGTGAGGTCCA AACGTGAAGAAAAGTTTACGC
Wt1 exon 10 TGGTGATTTAACTCAGGCCTTT CCCAGTGCTAGTGTTCAGAGTG
1500034J20Rik exon 1 CACAGACCGGGAGCTGAG CCCAAGAGGTGAGAGAGGC
1500034J20Rik exon 2 TCCTTCCTTAAATTCTCTTTTGG TGACTATAACAATGTCCCCGC
1500034J20Rik exon 3 TGGTTATCTTAAGTCATGAACTCAG TC TCTGGACTACAGGTGTGTGGAC
1500034J20Rik exon 4 GGCAAAAATTAGAAGCAAAGATAC AAGACACAGTGACCACAGACAC
1500034J20Rik exon 5 TTTATGACATTGATGTGTTCTGACTC GCTCAAACTTGGGTCCTCTG
1500034J20Rik exon 6 TTCATATAGGGTTTGTGTAGCTCATC GGGGAGAGGATAATGTTTTGTC
1500034J20Rik exon 7 ATTGATACACTAAACTGAATTTCTGG TTTGTTTTGGGTCAATTTTTATC
Elp4 exon 1 GACTTTGGGGCTAGCTCTGAC AAGAGAGGGAAAAAGGAAATGG
Elp4 exon 2 CACTGAGCACAGTAGTGCAAAA TGGAGCACAGTGAAGAGTAAAC
Elp4 exon 3 TCTCTTAGGCTCTCTGCTTTCG AAAACCCAAAAACCCAAAAATC
Elp4 exon 4 TGCTGTCATTA TGGTTCAAGAAA GGTGGAGAGAGATGGAAGACAC
Elp4 exon 5 CATGGATATGCCATTACTTTGC TCTTGGTATCCAGGCCTATCAT
Elp4 exon 6 GAAACTAAGTAACTGACCCTCT TGTGTGCATCCTGAGA ATCTAG
Elp4 exon 7 TCGTCTTCCTGATATTGTGAGT 5' CCAACAAAA ATGGACAAAAACC
Elp4 exon 8 CCTCCACTAAGATTTGTAAGAT TAAGCCACTGGCACAACAATAC
Elp4 exon 9 TTTAAAGGGAGGATGCTTGTGT TCATTTGAGTTTGGAGCTTATT
Elp4 exon 10 CTCTCACC ATGTACCCCAGC AAACTTAAGGATGGTGGCTCC
Hs.Dnajc20 exon 1 AGGAGGAGAGAAGCGACAG GGGAATCTTCTCCATTCACAG
Hs.Dnajc20 exon 2 ATCTGTGCTTCCTCAGGTTTG ATTAATACCTGGATTCCTGCC
Hs.Dnajc20 exon 3 TGTTGTCTCATTGCCTTGG AGGCAACAATAACACTTGGTG
Hs.Dnajc20 exon 4 TGATAGGTAAGTTAGAATTGTAGTGGC CTCCAGACAGAAACACTTACCAC
Hs.Dnajc20 exon 5.1 TCTGCACCTTTTAAGGGTATTAG GAAACGTTATCGGTTAGACCAG
Hs.Dnajc20 exon 5.2 TCCCATCTGAGAACTTTATTATGTC ACAAAACTTAGGCCAGGCAC
Hs.Dnajc20 exon 5.3 TGATATAATATTGGGGCCAGG TAGTCTACATGCTCAGCCCAC
Hs.Dnajc20 exon 5.4 ACTGCTGCTATGCTGAAATG CCTAATGGCCACAGATTTTC
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After mixing and briefly centrifuging the reactions are placed in a Peltier Thermal
Cycler (MJ Research). The standard cycling programme used was:
Step 1 5 minute denaturation, followed by 35 cycles of steps 2 to 4.
Step 2 1 minute at 94°C
Step 3 1 minute at 58°C
Step 4 1 minute 30 seconds at 68°C
Step 5 10 minutes at 68°C, final elongation
Step 6 4°C
This cycling programme works for the majority of primer pairs, however, if PCR failed,
the annealing temperature was changed to 55°C and 60°C and repeated.
7.1.6 Reverse-transcription polymerase chain reaction (RT-PCR)
RT-PCR was perfonned using the Access RT-PCR System (Promega). After defrosting
on ice, the following were mixed to a final volume of 50pl:
AMV/7)7 buffer (IX) 10pi
dNTPMix (lOmM) lpl
Forward Primer (100pM) 0.5 pi
Reverse Primer (1OOpM) 0.5pi
25mM MgS04 (lOOmM) 2pl
AMV Reverse transcriptase 1 pi
Tfl DNA polymerase 1 pi
Nuclease free dFFO 34pl
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After mixing and briefly centrifuging the reactions are placed in a Peltier Thermal
Cycler (MJ Research). The standard cycling programme used was:
Step 1 48°C for 45 minutes
Step 2 94°C for 2 minutes, followed by 40 cycles of steps 3 to 5
Step 3 94°C for 30 seconds
Step 4 60°C for 1 minute
Step 5 68°C for 2 minutes
Step 6 68°C for 7 minutes
Step 8 4°C
Table 7.2 shows the primers used for RT-PCR and cloning.
Table 7.2 Primers for RT-PCR and cloning
Primers Forward primer 5' to 3' Reverse Primer 5' to 3'
Dnajc20 Exon
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7.1.7 Gel Electrophoresis
Agarose gels were used to determine the presence and size of nucleic acid molecules.
The required amount of High pure agarose (BioGene) was dissolved in IX TBE by
microwaving. Ethidium bromide was then added to a final concentration of 500ng/ml.
The agarose was poured in to sealed plastic trays, a comb inserted, and the gel left to set.
Samples were run in IX gel loading buffer. The marker routinely used was PhiX174
DNAJHaelll (Promega). If large nucleic acid molecules (>lkb) or greater resolution
was required, NuSieve 3:1 agarose (FMC Bioproducts) was used (prepared as above).
After electrophoresis, gels were visualised by UV trans-illumination and a photographic
record produced.
7.1.8 Restriction Digests
Digests were performed using Roche or New England Biolabs enzymes and buffers.
The restriction enzyme was added to DNA in a 5 pi reaction with the appropriate buffer,
and incubated at 37°C for 2 hours. The enzymes used for cloning Dnajc20 in to the
pGEX-KG vector for antibody production were Xbal at the N-terminal and Hindlll at
the C-terminal. For cloning Dnajc20 in to the p3xFLAG-CMV™-10 (Sigma) for
localisation studies Hindlll was used to cut the N-terminal, and EcoRl was used to cut
the C-terminal.
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7.1.9 Ligations
Ligations were perfonned using the pGEX-KG bacterial overexpression vector and the
p3xFLAG-CMV™-10 (Sigma) mammalian expression vector. An amplified Dnajc20
RT-PCR product, using the appropriate primers (Table 7.2), was digested using the
appropriate restriction enzymes. The digested product was purified using a PCR
purification kit (Qiagen) and was used as an insert. The vectors were digested with the
appropriate enzymes and the products separated by electrophoresis on a NuSieve 3:1 gel.
The appropriate nucleic acid molecule was purified using a Gel Purification kit
(Promega). To maximise efficiency, ligation reactions were set up with the following
vector:insert molar ratios; 1:3, 1:1, and 3:1. A vector only control and an insert only
control were routinely undertaken. The vector and insert nucleic acid molecules were
mixed with DNA ligase and incubated at 4°C for 4 hours. Ligations were confirmed by
gel electrophoresis.
7.2 Microbiology
Aseptic technique was used for all procedures involving the growth of bacterial cells.
All liquid cultures were grown with vigorous shaking in an orbital shaker (220rpm), and
dry cultures were inverted and incubated overnight at 37°C.
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7.2.1 Solutions
All reagents were analytical grade and supplied by Sigma, Invitrogen, BDH, Roche,
Qiagen and Fisher and stored at 4°C unless otherwise stated. Bacterial growth media












dFhO was added to a final volume of 1 litre.
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Ampicillin, 1000X
100 mg Ampicillin (D-[-]-a-aminobenzylpenicillin sodium salt) was diluted in 2ml
ethanol and stored at -20°C. Ampicillin was used at a working concentration 50pg/ml.
7.2.2 Competent cells preparation
Calcium competent BL21 E. coli cells were prepared for overexpression of the GST
tagged Dnajc20 protein from the pGEX-KG vector. BL21 cells were grown overnight in
100ml of L-broth to saturation. The culture is then centrifuged at 3,200 rpm at 4°C to
collect the cells. The cells are re-suspended in 20ml of 0.1M CaCl2 for 15 minutes on
ice. The cells are centrifuged at 4°C for 5 minutes at 3,000 rpm. The supernatant is
removed, and the cells re-suspended in 2ml of 0.1M CaCl2. The competent cells are
kept cold at all times and either used immediately or snap frozen and stored at -70°C.
7.2.3 Transformations
Heat shock transformations were performed by adding 5pl of DNA ligation mix to 95pl
of thawed DH5a sub-cloning efficiency E. coli (Life Technologies), or calcium
competent BL21 cells, in a 1,5ml round bottomed centrifuge tube on ice. The DNA/cell
suspension is incubated on ice for 30 minutes, then immersed in a 37°C waterbath for 45
seconds, followed by incubation on ice for 2 minutes. The transformed cells are then
suspended in 1ml of L-broth and incubated at 37°C in an orbital shaker for 1 hour.
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Using an inoculation loop, the bacteria are spread on to a L-agar plate containing IX
ampicillin (both vectors used are selected by ampicillin resistance). Normally two plates
would be used for each transformation, one spread with 50pl and one with 350pl. The
L-agar plates are inverted and incubated overnight at 37°C. Control experiments are
performed where the original, undigested vector, and untransformed cells are also
plated.
7.2.4 Isolation of plasmid DNA
Plasmid DNA was prepared using either the Qiagen miniprep or maxiprep kits. For the
extraction of a small amount of plasmid DNA the miniprep kit is used. A single colony
is used to inoculate 5ml of L-broth containing IX ampicillin. The culture is grown at
37°C overnight in an orbital shaker. The following day, plasmid DNA is extracted using
the kit, according to the manufacturers instructions. For recovery of large amounts of
plasmid DNA a maxiprep is performed. A single colony is used to inoculate 5ml of L-
broth and is grown overnight, as before. The following day the culture is stored at 4°C,
before being used to inoculate 100ml of L-broth and is grown in an orbital shaker
overnight. The following day a maxiprep is performed according to the manufacturers
instructions.
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7.2.5 Overexpression from the pGEX-KG vector
Transformed BL21 cells are grown overnight in 20ml of L-broth at 37°C in an orbital
shaker. The following morning this preculture is added to 400ml of L-broth and grown
until the optical density (OD) is between 0.4 and 0.8, approximately 3 hours (1ml of the
culture is removed as a -IPTG control sample). 2ml of 20mg/ml 1PTG (isopropyl-beta-
D-thiogalactopyranoside) is added to the culture to induce expression from the pGEX-
KG vector. The IPTG induces expression by inhibiting the lac repressor, allowing
expression from the lacZ promoter. The culture is then grown at 30°C for 4 hours.
After these 4 hours 1ml of the sample is removed as a +IPTG control sample. The
culture is centrifuged at 4,000rpm for 30 minutes at 4°C and the supernatant removed
(the pellet can be stored at -70°C). The pellet is re-suspended in 20ml of GST binding
buffer (see 7.3 Protein manipulations). The sample can then be stored, or the protein
extracted by sonication.
7.3 Protein manipulation
All reagents and solutions were analytical grade and supplied by Sigma, Invitrogen
(Novex), Bio-rad) and Fisher. General lab solutions are prepared by HGU technical
service staff, autoclaved, and stored at 4°C unless otherwise stated. All protocols are
performed on ice, unless stated otherwise.
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7.3.1 Solutions
GST Binding buffer











Dissolve in 800ml dH20, adjust the pH to 7.4 with concentrated HC1. Adjust volume to
1 litre and divide in to aliquots for dilution to IX.
PBT
Add 1ml Tween-20 to 1 litre PBS.
Thrombin protease
Dissolve 500pg in 0.5ml PBS. Aliquot as 50pl working stocks. Snap freeze and store at
-70°C.
Modified RIPA buffer. IX
Tris.HCl pH 7.4 50mM
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Add the APS and Temed immediately before pouring the gel. Pour a layer of dH20 on














Add the APS and Temed immediately before pouring the gel. Insert the comb, and leave
to set (30 minutes).
SDS Loading buffer. 2X










Bromophenol blue (1%) 2ml
Adjust volume to 20ml with d
mercaptoethanol (fume hood).
Immediately prior to use add 50pi p-
Running buffer, 5X
Glycine 94g
Tris Base 15.1 g
SDS 5g
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Dissolve in 800ml dH20 to dissolve. Adjust volume to 1 litre with dFFO.





Add 1.6 litres dH20 to dissolve. Add 400ml methanol.
7.3.2 Purification of GST fused Dnajc20
Following overexpression of GST fused Dnajc20 from the pGEX-KG, the protein is
extracted by sonication. A 1 ml control solubility sample is removed, and centrifuged for
5 minutes at 13,000rpm. The supernatant is mixed with an equal volume of SDS loading
buffer and 1ml of cracking buffer is added to the pellet. The samples are separated by
SDS-PAGE (7.3.4) along with the -IPTG and +IPTG control samples (7.2.4), and
protein visualised by GelCode® Blue Stain Reagent (Pierce) (7.3.7). If the GST fused
Dnajc20 protein has been overexpressed and is present in the soluble sample it can be
purified. The total sonicated sample is centrifuged for 30 minutes at 4°C. The
supernatant is transferred to a fresh 50ml falcon tube. To the sample add 400pl ofGS4B
sepharose beads (Amersham Biosciences) that are in a 1:1 slurry with PBS. The
sample/beads are turned on a wheel for 2 hours at 4°C allowing the GST fused Dnajc20
to bind to the beads. Following binding the supernatant is removed to the top of the
beads. The beads are washed 5 times in 4ml of GST binding buffer, with 1minute
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centrifugation at 6,500rpm at 4°C between washes. An aliquot of beads can be boiled in
SDS loading buffer, and the sample run by SDS-PAGE to confirm purification. The
Dnajc20 protein was removed from the beads by thrombin cleavage. Add 14jul of
thrombin from working stock to 130pl of PBS. GST binding buffer is removed from the
beads and replaced with the diluted thrombin protease. Overnight, the sample is turned
on a wheel at room temperature. The Dnajc20 protein is present in the supernatant, and
can be confirmed by SDS-PAGE.
7.3.3 Extraction of protein from E10.5 embryos
Immediately following dissection of El0.5 embryos, each embryo is added to a 1.5ml
centrifuge tube containing ice-cold modified RIPA buffer. Each sample is kept on ice
for 30 minutes. Every 5 to 10 minutes the embryo is pipetted to break up the tissue.
After 30 minutes the samples are centrifuged for 15 minutes at 4°C. Following
centrifugation the supernatant (containing soluble protein) is transferred to a fresh 1,5ml
centrifuge tube (this can be stored at -20°C, but avoid repeated freeze-thaw cycles). To
run by either SDS-PAGE or Native-PAGE add an equal volume of the appropriate
loading buffer. The pellet can also be kept and Cracking buffer added to investigate the
insoluble protein.
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7.3.4 SDS-PAGE
The composition of the gel varied, depending upon the protein being detected but
routinely a 12% minigel was used to separate proteins according to molecular weight.
The gel apparatus was assembled (Bio-rad) and the gel allowed to set at room
temperature. The samples were boiled for either 5 minutes in SDS-loading buffer, or 10
minutes in Cracking buffer. Alongside the samples either the Precision Plus Protein™
Kaleidoscope™ protein marker (Bio-rad) or the Prestained protein marker Broad range
(P77083, Biolabs) was loaded. Running buffer was added to the gel, and the gel run at
200V for 45-60 minutes. The gel was then either transferred to Hybond-P (Amersham
biosciences) for Western blot analysis, or GelCode® Blue Stain Reagent (Pierce) used to
detect total protein.
7.3.5 Native-PAGE
Protein from E10.5 embryos was separated by Native-PAGE for investigation of
diphthamide on eEF2. Pre-cast 4%-12% Tris-glycine gels (Novex) were used as per the
manufacturers instructions. Prior to loading, the protein extract was incubated for 10
minutes at room temperature in IX native sample buffer (Novex). 10X native-running
buffer (Novex) was diluted and added to the gel system (Novex). The samples were run
four 4 hours at 125V. The gels were then transferred to Hybond-P for Western blot
analysis.
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7.3.6 Western blot analysis
A wet blotter was used to transfer proteins onto a Hybond-P filter. The samples were set
up in the blotter apparatus following soaking of the pads in transfer buffer, and filling
the tank with transfer buffer. From the cathode plate as follows; 1st plastic mesh, 3 wet
pads, 1 piece of filter paper cut to the size of the gel and soaked in transfer buffer, the
gel washed in transfer buffer (being careful to remove air bubbles), the Hybond-P
membrane, soaked in methanol (being careful to remove air bubbles), the second section
of filter paper, the remaining wet pads, the 2nd mesh and finally the anode plate and
plastic cover. The tank was topped up with transfer buffer and the transfer carried out
for 60 minutes.
Once the transfer had taken place, the blot was probed for the protein of interest. Firstly,
the hybond-P was blocked in 5% fat free milk in PBT at 4°C overnight (room
temperature overnight when probing for the Dnajc20 protein). The primary antibody (a-
eEF2, sc-13004 from Santa Cruz, used at a concentration of lin 500. a-Dnajc20, see
7.3.8, used at a concentration of 1 in 500) was then added to fresh 5% fat free milk in
PBT and incubated with the blot for 1 hour at room temperature. Following incubation
with the primary antibody, 3x15 minute washes were performed with PBT at room
temperature. Following completion of the washes the secondary antibody, conjugated
with horseradish peroxidase, was then added in fresh 5% fat free milk in PBT (for eEF2,
sc-2020 donkey anti-goat, Santa Cruz at 1 in 5000. For Dnajc20, NA934VS anti-rabbit,
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Molecular Probes, at 1 in 10,000) for 45 minutes at room temperature. After the
incubation, the blot is then washed for 3 x 15 minutes in PBT. Detection of the protein
was carried out using ECL-plus (Amersham Biosciences) as described by the
manufacturer. Bands were visualised by incubating for 1 minute with Kodak BioMax
XAR films in and developed using an X-ray processor.
7.3.7 Visualisation of total protein
To visualise total protein GelCode® Blue Stain Reagent (Pierce) was used according to
the manufacturers instructions. Briefly, following SDS-PAGE the gel is placed in a
microwave proof tray with 100ml of ultrapure water and heated for 90 seconds. The
water is replaced with 100ml of fresh ultrapure water and microwaved again for 90
seconds. The water is replaced with fresh ultrapure water and washed for 5 minutes.
The water is then replaced with 50ml of GelCode® Blue Stain Reagent (Pierce) to
completely cover the gel, and microwaved for 1 minute. After the microwave step,
incubate for 5 minutes at room temperature. Following the staining the gel is washed for
at least 10 minutes in 200ml of ultrapure water. Longer washes, regularly changing the
water, can reduce background. The gel then can be dried using a vacuum dryer, and
stored indefinitely.
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7.3.8 Production of an antibody against Dnajc20
The full-length Dnajc20 gene was amplified by RT-PCR and cloned into the pGEX-KG
vector (7.1.6 to 7.1.9). A GST fused Dnajc20 construct was then produced by
overexpression in BL21 E. coli (7.2.4) and purified by GST pull-down and thrombin
cleavage (7.3.2). The full-length Dnajc20 protein was the sent on ice to Diagnostics
Scotland for contract immunisation. The anti-Dnajc20 antibody was raised in a single
rabbit. A pre-immunisation bleed was taken, followed by bleeds at month 1 and month
2 following immunisation. At month 3 the rabbit was exsanguinated. This final bleed
was used directly in Western analysis against the purified Dnajc20 protein and found to
detect a single band corresponding to the expected size. This sera detects multiple bands
by Western analysis against total protein from El0.5 embryos, including a band of
around 17kDa, which corresponds to the expected size of the Dnajc20 protein. This
band is absent in Western analysis performed protein from El0.5 Dnajc20 homozygous
mutant embryos.
7.4 Mammalian cell culture and immunofluorescence
All reagents were produced by EIGU technical service staff and stored at 4°C unless
otherwise stated. All tissue culture was performed in tissue culture hoods.
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7.4.1 Reagents and solutions
Tissue culture media
Dulbecco's media (DMEM) 500ml
Fetal Calf Serum (FCS) 50ml
Penicillin/streptomycin 5ml
Glutamine 5ml




Mix together and store at -20°C until needed. Heat in a waterbath at 37°C for 30




Heat PBS for 1 minute in a microwave. Add to PFA in a fume hood and allow to
dissolve. Prior to use the 4% PFA should be ice cold.
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7.4.2 Cell culture and splitting
NIH-3T3 cells were routinely used. Cell lines were maintained at 37°C with 5% CO2 in
tissue culture media. Cells were grown in 10cm petri dishes in 10ml tissue culture
media to near confluence. To split the cells, the media is poured off, followed by two
washes in PBS (37°C). 1ml of trypsin is then added, and incubated for 5 minutes at
37°C. Gentle agitation dislodges the cells, and 9ml fresh tissue culture media added.
Repeated pipetting separates toe cells. 1ml of this is added to a new 10cm petri dish
containing 9ml fresh tissue culture media.
7.4.3 Transfection of NIH-3T3
NIH-3T3 cells are seeded onto coverslips in 6-well plates, and grown to >90%
confluence. For each well, 5pl Lipofectamine 2000 (Invitrogen) is added to 200pl of
Opti-MEM (Invitrogen), gently mixed, and incubated for 5 minutes at room temperature.
2pg of the DNA for transfection is incubated with 200pl of Opti-MEM and incubated
for 5 minutes. Following incubation, the two mixtures are combined, mixed gently, and
incubated at room temperature for a further 20 minutes. The mixture is then added to
the well by drop-wise addition, while the 6-well plate is rocked gently from side-to-side.
The cells are then incubated for 44 to 48 hours. The tissue culture media is not replaced.
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7.4.4 Immunofluorescence on fixed cells
Following transfcction of cells and growth on coverslips, 2 washes in ice-cold PBS were
performed. After this ice-cold 4% PFA was added, and the cells fixed on ice for 10
minutes followed by 2 x 5 minute washes in PBT washes in P. Cells were then blocked
for 1 hour at room temperature in PBS containing azide and BSA (bovine serum
albumin). Following blocking, the primary antibody was added to fresh PBS-azide-BSA
to a total volume of 400pl (either anti-FLAG M2 monoclonal F-3165, Sigma, at a
concentration of 1 in 200, or C-Myc (A-14) sc-789, Santa cruz, at a concentration of 1 in
100) and incubated for 1 hour at room temperature on a rack. After incubation, 3x5
minute washes in PBT were carried out. The secondary antibodies or stains were then
added to fresh PBS-azide-BSA to a total volume of 400pl (anti-Mouse Texas Red, 715-
075-150, Stratech, at a concentration of 1 in 400. anti-mouse Alexa 488, 715-095-150,
Stratatech. anti-Rabbit Alexa 488, A11034, Molecular probes, at a concentration of 1 in
400. Phalloidin R415, Molecular probes, at a concentration of 1 in 200). Incubation was
performed on racks at room temperature in the dark. Following incubation, 3x5 minute
washes in PBT were performed. Coverslips were mounted on to slides in Vectashield
(Vector). Coverslips were sealed using vulcanising solution (REMA Tip Top), and
slides stored at 4°C in the dark.
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7.5 Computational methods
7.5.1 Programs and databases
BLAST (version 2.1) Altschul et al 1997.




ClustalW (version 1.74) Thompson et al 1994168
Sequence alignment program.
Ensembl (Multiple builds) Clamp et al 2003169
INTERPRO Apweiler et al 2001
http://www.ensembl.org/Mus musculus/protview?db=core;peptide=ENSMUSP00000030118
GeneDoc Nicholas et al (unpublished)170
Mouse Genome Informatics (MG1)
http://www.informatics.iax.org/
Pfam Bateman A et al (2000)171
www. sanger.ac.uk/Software/Pfam/
PSORT II Nakai K and Horton P (1999)52
http://psort.nibb.ac.ip/forip2.html
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SMART Schultz et al 1998172. Letunic et al 2004''73
http://smart.embl-heidelberg.de/
7.5.2 Identification of mouse J-proteins
Protein sequences, annotated as J-proteins, were retrieved from the MGI database
(according to name) and the Ensembl database (according to the presence of the
INTERPRO IPR001623 entry). The proteins were confirmed in the Ensembl database,
and the J-protein omitted if it did not have a proper gene structure. BLAST searches
were performed with each of the J-proteins to identify any proteins represented more
than once in the dataset. This J-protein dataset was then entered in to the SMART
database to confirm the presence of a defined J-domain based upon the Pfam annotation.
This resulted in the final dataset of mouse J-proteins. Initial characterisation of domain
structure was performed on the entire dataset through SMART analysis. Novel J-
proteins were subjected to PSORT II analysis for characterisation.
7.5.3 Identification of sequence orthologues of Dnajc20
The protein sequence of the mouse Dnajc20 protein was used in 3 iteration PS I- and
PHI-BLAST searches to identify protein orthologues. The J-domain containing
sequence was masked to reduce results that identify other J-proteins. If a sequence
showed homology to the C-terminal region of Dnajc20 it was investigated for the
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presence of an N-terminal J-domain. This analysis also identified the presence of the
small zf-CSL proteins. Many of the proteins have subsequently been annotated as zf-
CSL proteins by Pfam.
7.5.4 Alignment of protein sequence
Protein sequence alignments were created using ClustalW, with an MSF output. The
alignments were visualised using GeneDoc.
7.6 Mouse Husbandry
All animals were maintained in the BRF facility by University of Edinburgh staff and
Lisa Mckie, a member of our group. Wild-type mice were bred in-house. Embryos
from all experiments were generated from timed matings, with the morning of vaginal
plug detection being counted as embryonic day 0.5. Tissue for genotyping was obtained
by ear-clipping following weaning.
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7.7 Microscopy
7.7.1 Wholemount microscopy
Dissected embryos were imaged with a Leica Stereo MZFLIII stereofluorescence
microscope (Leica Microsystems Milton Keynes, UK). Embryos were illuminated from
above by a separate light source. Images of whole embryos under PBS were captured
from above with a Photometries CoolSnap colour CCD camera (Roper Scientific,
Arizona) controlled scripts written for IPLab Spectrum (Scanalytics, VA).
7.7.2 Fluorescence imaging of cells
Slides for immunofluorescence experiments were examined using a Zeiss Axioplan II
fluorescence microscope with 100 watt mercury bulbs and equipped with a triple band¬
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